WO1993003030A1 - Quinoline derivatives as immunostimulants - Google Patents

Quinoline derivatives as immunostimulants Download PDF

Info

Publication number
WO1993003030A1
WO1993003030A1 PCT/US1992/005435 US9205435W WO9303030A1 WO 1993003030 A1 WO1993003030 A1 WO 1993003030A1 US 9205435 W US9205435 W US 9205435W WO 9303030 A1 WO9303030 A1 WO 9303030A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino
quinoline
hydrochloride
alkyl
pyrazolo
Prior art date
Application number
PCT/US1992/005435
Other languages
French (fr)
Inventor
Mikel P. Moyer
James W. Mcfarland
Original Assignee
Pfizer Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc. filed Critical Pfizer Inc.
Priority to EP92916871A priority Critical patent/EP0597003A1/en
Priority to US08/190,113 priority patent/US5506235A/en
Priority to JP5503553A priority patent/JPH06504294A/en
Publication of WO1993003030A1 publication Critical patent/WO1993003030A1/en
Priority to FI940469A priority patent/FI940469A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C07D215/44—Nitrogen atoms attached in position 4 with aryl radicals attached to said nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Definitions

  • the present invention relates to novel guinoline derivatives that exhibit activity as immunostimulants.
  • the compounds of this invention increase the host's resistance to infection or infestation by bacteria, viruses, fungi, etc. They are therefore useful, alone or in combination with anti- infective therapy, in the prophylactic or therapeutic treatment of any infectious disease.
  • U.S. Patent No. 4,716,168, assigned to Norwich Eaton Pharmaceuticals, Inc. refers to other quinoline derivatives, more specifically, to imidazo(4,5-f)quinolines, and states that such compounds are useful in enhancing the immune response system of a mammal.
  • R 1 is (C 3 -C 18 ) alkyl or phenyl optionally substituted with from one to three substituents independently selected from (Cj-Cg) alkyl, (C,-C 6 ) alkoxy, halo, cyano, (C 3 -C 8 ) cycloalkyl-(Cj-C 6 )alkoxy wherein the cycloalkyl moiety may be substituted with from one to three (Cj-Cg)alkyl groups; hydroxyl, benzyloxy, carboxyl, hydroxy-(C j -C 6 ) alkyl, pyrrolidino, piperidino, orpholino and -CONHQCOOH wherein Q is (C 1 -C 4 ) alkyl;
  • R 8 and R 9 are independently selected from hydrogen, phenyl and alkyl
  • R 11 , R 12 , R 13 and R 14 are independently selected from (C x - C 6 ) alkyl and phenyl optionally substituted with halo, (C j -
  • This invention also relates to the pharmaceutically acceptable acid addition salts and cationic salts of compounds of the formula I.
  • halo includes fluoro, chloro, bromo and iodo.
  • alkyl may be straight, branched or cyclic, and may include straight and cyclic moieties as well as branched and cyclic moieties.
  • the compounds of formula I may have chiral centers and therefore may occur in different stereoisomeric configurations.
  • the invention includes all stereoisomers of such compounds of formula I, including mixtures thereof.
  • the present invention also relates to all radiolabelled forms of the compounds of the formula I. Such radiolabelled compounds are useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays in both animals and man.
  • the present invention also relates to a pharmaceutical composition for enhancing or stimulating the immune response of vertebrates, including humans, cattle, swine and poultry, comprising an immune response enhancing or stimulating amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
  • the present invention also relates to a met ⁇ od for enhancing or stimulating the immune response of verteorates, including humans, cattle, swine and poultry, comprising administering to a vertebrate an immune response enhancing or stimulating amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.
  • Preferred compounds of this invention are compounds of the formula I wherein R 3 , R 6 and R 7 are hydrogen, and R 4 and R 5 , together with the carbons to which they are attached, form a group of the formula
  • R 3 , R 4 , R 6 and R 7 are hydrogen and R 5 is amino, -NHS0 2 R u , -NHCOR 12 or hydroxy.
  • Specific preferred compounds of this invention are: 9- (m-Anisidino) -7-methyl-lH-pyrazolo [3 , 4-f ] quinoline hydrochloride ;
  • 6-Amino-4- (m-anisidino) quinoline; 6-Amino-4- (p-butoxyanilino) quinoline ;
  • Examples of other compounds of the formula I include: 7-methyl-9- (4-pyrrolidinoanilino) -lH-pyrazolo[3 , 4-f] - quinoline hydrochloride;
  • 6-acetamidino-4- (m-anisidino) quinoline hydrochloride 7-acetamidino-4- (m-anisidino) quinoline hydrochloride
  • R 15 is methyl or ethyl.
  • This reaction is generally carried out in an inert solvent such as ethyl ether, a halogenated hydrocarbon, dimethylformamide (DMF) , acetonitrile or a lower alcohol, preferably ethanol, at a temperature from about ambient temperature to about the reflux temperature of the solvent, preferably from about 40°C to about 100°C.
  • an inert solvent such as ethyl ether, a halogenated hydrocarbon, dimethylformamide (DMF) , acetonitrile or a lower alcohol, preferably ethanol
  • condensation reaction is carried out by reacting a alonate of the formula VII
  • each R 15 is independently selected from methyl and ethyl, with an amine the formula II in an inert solvent, preferably toluene, at a temperature from about ambient temperature to about the reflux temperature of the solvent, preferable from about 20°C to about 120°C.
  • the compound of formula III produced in the foregoing reaction may be cyclized by heating it in a high boiling, inert solvent (e.g., xylenes, mesitylene or diphenyl ether), preferably diphenyl ether/biphenyl (Dowtherm, trademark) , at a temperature from about 140°C to about 270°C, preferably about 250°C.
  • a high boiling, inert solvent e.g., xylenes, mesitylene or diphenyl ether
  • diphenyl ether/biphenyl e.g., xylenes, mesitylene or diphenyl ether
  • the condensation reaction using a compound of the formula VII and the subsequent cyclization reactions described above produce compounds wherein R 3 is -COOR 15 .
  • These esters can be converted to the corresponding carboxylic acids, and the resulting acids decarboxylated to form the corresponding compounds wherein R 3 is hydrogen.
  • the hydrolysis reaction is typically conducted using an alkali metal hydroxide in water, a lower alcohol, tetrahydrofuran (THF) , acetonitrile or . an aqueous mixture of these solvents. It is preferably in aqueous sodium hydroxide. Suitable temperatures for this reaction range from about room temperature to about the reflux temperature of the solvent. The reflux temperature is preferred.
  • the decarboxylation is generally carried out by heating the acid in an inert solvent (e.g., quinaldine, diphenyl ether or mesitylene), preferably in diphenyl ether/biphenyl (Dowtherm, trademark) , at a temperature from about 150°C to about 280°C, preferably about 250°C.
  • an inert solvent e.g., quinaldine, diphenyl ether or mesitylene
  • Compounds of the formula V may be converted to the corresponding compounds of formula I by reacting them with the appropriate amine of the formula HNR 1 neat or in an inert solvent such as a lower alcohol, a halogenated hydrocarbon or (DMF) , preferably ethanol, at a temperature from about ambient temperature to about 180°C, depending on the reactivity of the particular amine.
  • the preferred solvent is ethanol.
  • Compounds of the formula I wherein R 5 , R 6 or R 7 is amino may be prepared by reduction of the corresponding compounds wherein R 5 , R 6 or R 7 , respectively, is nitro using methods well known in the art. (See March, “Advanced Organic Chemistry", pp. 1125-1126, McGraw-Hill Book Company, New York, 1977) . It is preferable to use hydrogen gas at a pressure of about 1 atmosphere in the presence of palladium on carbon, and to conduct ' the reaction in a. lower alcohol solvent at about room temperature.
  • the pharmaceutically acceptable acid addition salts of compounds of the formula I are prepared in a conventional manner by treating a solution or suspension of the free base of formula I with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts.
  • pharmaceutically acceptable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, methanesulfonic, cinnamic, fumari ⁇ , phosphonic, hydrochloric, hydrobromic, hydroiodic, sulfamic and sulfonic acid.
  • the active compounds of this invention and their pharmaceutically acceptable acid addition salts are useful in stimulating, restoring or enhancing the immune response of a host vertebrate, thus increasing the host's resistance to infection or infestation by bacteria, viruses, fungi, etc. They are therefore useful, alone or in combination with antiinfective therapy, in the prophylactic or therapeutic treatment of any infectious disease.
  • the activity of the compounds of this invention as immunostimulants may be determined by the following procedure.
  • mice (Harlan Sprague Dawley, female) in the control group (i.e., those not receiving drug) and those in the experimental group are infected with E. coli 51A760 (2 x 10 7 colony forming units) by intraperitoneal injection.
  • a subtherapeutic dose of gentamicin (0.5 mg/kg) may be optionally administered subcutaneously to mice in both the experimental and the control group 0.5, 4, and 24 hours after such injection) .
  • Twenty-four hours before the injection with E. coli the mice in the experimental group are treated subcutaneously with drug dissolved or suspended in pyrogen-free saline. The number of surviving mice in the control and experimental groups 96 hours after such infection is recorded.
  • a compound is considered active if the number of surviving mice in the experimental group is significantly higher than those surviving in the control group.
  • the compounds of this invention may be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. They can be injected parenterally, for example, intramuscularly, intravenously or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which can contain other solutes, for example, enough salt or glucose to make the solution isotonic. In the case of vertebrates other than humans, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1-50 mg/kg/day, advantageously 0.2-10 mg/kg/day given in a single daily dose or up to 3 divided doses.
  • the compounds of this invention can be administered to humans for the treatment of bacterial diseases by the parenteral route.
  • dosage levels are about 0.1-200 mg/kg/day, advantageously 0.5-50 mg/kg/day.
  • intramuscular administration may consist of a single dose or up to 3 divided doses
  • intravenous administration can consist of a continuous drip. Variations will necessarily occur depending on the weight and condition of the subject being treated and the particular route of administration chosen, as will be known to those skilled in the art.
  • the present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these exa ples. Melting points are uncorrected.
  • Proton nuclear magnetic resonance spectra (*H NMR) and 13 C nuclear magnetic resonance spectra ( 13 C NMR) were measured for solutions in deuterodimethylsulfoxide (d 6 -DMSO) and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane (TMS) .
  • the peak shapes are denoted as follows: s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet; br, broad; c, complex.
  • the title compound was prepared by the method described in Example 1 with the modification that 5-aminobenzotriazole was used as the starting material instead of 6- aminoindazole.
  • 6-Aminoindazole (10.00 g, 75 mmol) was suspended in toluene (150 ml) to which diethyl ethoxymethylene alonate
  • EXAMPLE 30 6-Amino-4-(p-butoxyanilino) uinoline hydrochloride
  • the title compound was prepared from the corresponding 6-nitro compound by catalytic reduction of the nitro group followed by treatment with HCl in ether.
  • the 6-nitro-4-(p- butoxyanilino)quinoline compound was prepared in an analogous fashion to Example 9 with the modification that 4- nitroaniline was used as the starting material instead of 6- aminoindazole and p-butoxyaniline was used in the displacement of the 4-chloro substituent instead of m- anisidine.
  • This compound was prepared from the corresponding 6- amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline with trichloroacetyl isocyante in THF followed by cleavage of the trichloroacetyl group with methanol/sulfuric acid.
  • the hydrochloride salt was formed by treatment with HCl in ether.
  • This compound was prepared from the corresponding 6- amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline with acetic anhydride, DMAP, and triethylamine in methylene chloride, followed by treament with HCl to form the hydrochloric salt.
  • N- ( 4 -Butylphenyl ) -6-methoxy-2-methylquinolin-4- amine In a 100 mL three-neck round bottom flask under a nitrogen atmosphere and with magnetic stirring, a solution of 502 mg (2 . 42 mmol) of 4-chloro-6-methoxy-2-methyl- quinoline, 450 mg (3.02 mmol) of 4-butylaniline and 25 mL of ethanol was heated under reflux for an hour. The reaction solution was evaporated under reduced pressure to furnish a residue which was then chromatographed on silica gel (eluant 9:1 chloroform-methanol) to give 511 mg of the desired product. The sample was recrystallized from ethanol-water to give 320 mg (41%) of pure N-(4-butylphenyl)-6-methoxy-2- methylquinolin-4-amine: m.p. 200-201°C.
  • EXAMPLE 43 4-Dodecylamino-2-methylquinolin-6-ol Methanesulfonate A stirred mixture of 1.2 g (3.0 mmol) of the hydrochloride salt described in Example 42, ethyl acetate and water was adjusted to pH 8 by the addition of aqueous 4 N sodium hydroxide. The organic phase was evaporated under reduced pressure to afford 1.0 g (2.9 mmol) of the free base as a yellow solid. This was treated with an equivalent of methanesulfonic acid. The resulting solid was triturated with isopropyl ether and then recrystallized from acetonitrile to furnish 600 mg of the title product as golden needles: m.p. 123-125°C.
  • EXAMPLE 44 4-Decylamino-2-methylquinolin-6-ol Methanesulfonate In the manner similar to those described in Example 39, Part B, and Example 43, 4-chloro-2-methylquinolin-6-ol and decylamine (neat at 130°C) were transformed into the title compound: m.p. 100-102°C.
  • EXAMPLE 50 4-(Decylamino)quinolin-6-ol Hydrochloride In a manner similar to that described in Example 49, Part B, 4-chloroquinolin-6-ol and decylamine were transformed into the title compound as the hydrochloride salt: m.p. 197-199°C.
  • EXAMPLE 54 4-(Decylamino)-2-methylquinolin-7-ol Methanesulfonate In a manner similar to that described in Example 49, Part B, 4-chloro-2-methylquinolin-7-ol and decylamine were transformed into the title compound: m.p. 188-189°C.
  • EXAMPLE 57 4-(Dodecylamino)quinolin-8-ol Hydrochloride In a manner similar to that described in Example 49, Part B, 4-chloroquinolin-8-ol and n-dodecylamine were transformed into the title compound: m.p. 189-190°C; m/e 328 (molecular ion) ; NMR spectum consistent with assigned structure.
  • EXAMPLE 58 4-[4-(Cyclohexylmethyloxy)phenylamino.quinolin-6,8-diol Hydrochloride
  • reaction mixture Upon cooling to room temperature, the reaction mixture was diluted with isopropyl ether and filtered to furnish 18.7 g of 5-[ (2,4-dimethoxyphenyl)aminomethylene]- 2,2-dimethyl-l,3-dioxan-4,6-dione as a bright orange solid. This solid was then added portionwise to 80 L of a boiling solution of biphenyl and diphenyl ether/biphenyl, (Dowtherm, trademark) . After the final addition heating was continued for just 5 minutes. After cooling to room temperature, the reaction mixture was stored in the refrigerator overnight, and then stirred with isopropyl ether for an hour. The solids were filtered and washed with isopropyl ether to afford 11.8 g (83%) of 6,8-dimethoxyquinolin-4-ol: m.p. 221-224°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

This invention relates to compounds of formula (I) wherein R?1, R2, R3, R4, R5, R6 and R7¿ are as defined. These compounds exhibit activity as immunostimulants.

Description

QUINOLINE DERIVATIVES AS IMMUNOSTIMULANTS
The present invention relates to novel guinoline derivatives that exhibit activity as immunostimulants. By improving a host's immune response, the compounds of this invention increase the host's resistance to infection or infestation by bacteria, viruses, fungi, etc. They are therefore useful, alone or in combination with anti- infective therapy, in the prophylactic or therapeutic treatment of any infectious disease.
U.S. Patent No. 4,716,168, assigned to Norwich Eaton Pharmaceuticals, Inc. refers to other quinoline derivatives, more specifically, to imidazo(4,5-f)quinolines, and states that such compounds are useful in enhancing the immune response system of a mammal.
Summary of the Invention The present invention relates to compounds of the formula
Figure imgf000003_0001
wherein R1 is (C3-C18) alkyl or phenyl optionally substituted with from one to three substituents independently selected from (Cj-Cg) alkyl, (C,-C6) alkoxy, halo, cyano, (C3-C8) cycloalkyl-(Cj-C6)alkoxy wherein the cycloalkyl moiety may be substituted with from one to three (Cj-Cg)alkyl groups; hydroxyl, benzyloxy, carboxyl, hydroxy-(Cj-C6) alkyl, pyrrolidino, piperidino, orpholino and -CONHQCOOH wherein Q is (C1-C4) alkyl;
R2 is hydrogen, (C,-C6) alkyl, (C3-C7) cycloalkyl, phenyl or phenyl-(Cι-C6) alkyl, wherein the phenyl moieties of said phenyl and said phenyl-(C^Cg) alkyl may be optionally substituted with from one to three substituents independently selected from
Figure imgf000004_0001
-alkoxy, halo, cyano and benzyloxy; each of R3 and R4 is hydrogen; R5 is hydrogen, amino, hydroxyl, 5-pyrazolyl, guanidino, hydroxy-fCj-Cg) alkyl, -NHC(=NR8)R9, -NHS02Rn, -NHCOR12 or ureido; or R4 and R5, together with the carbons to which they are attached, form a group of the formula
Figure imgf000004_0002
wherein.the carbon of group A labelled with an asterisk (*) represents the point of attachment of R4 to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R5 to the quinoline nucleus;
R6 is hydrogen, hydroxyl, amino, guanidino, -NHC(=NR8)R9, -NHCOR13, -NHS02R13 or ureido; R7 is hydrogen, halo, hydroxyl, amino, -NHC(=NR8)R9, -NHS02R14, -NHCOR14, ureido or guanidino;
R8 and R9 are independently selected from hydrogen, phenyl and
Figure imgf000004_0003
alkyl;
R11, R12, R13 and R14 are independently selected from (Cx- C6) alkyl and phenyl optionally substituted with halo, (Cj-
C6)alkyl or (Cj-Cg)alkoxy; except for 6-amino-4-anilino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-phenylquinoline hydrochloride, 6-amino-4-cyclohexylamino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-methylquinoline methanesulfonate, 6-amino-4-(p-toluidino)-2-methylquinoline methanesulfonate, 9-(p-anisidino)-2-methyl-lH-pyrazolo[3,4- f] quinoline hydrochloride, 9- (cyclohexylamino) -1H- pyrazolo [ 3 , 4-f ] quinoline methanesulf onate , 9-
(cyclopentylamino) -lH-pyrazolo [3, 4-f ] quinoline methane¬ sulf onate, 4- (phenylamino) -2-phenylquinolin-6-ol hydrobromide; 4- (butylamino) -2-phenylquinolin-6-ol hydrobromide; 4-[ (3-methoxyphenyl) amino] -2-methyl- quinolin-7-ol hydrochloride; 4-[ (4-chlorophenyl) amino]-2- methylquinolin-7-ol hydrobromide; 4- (cyclohexylamino) -2- methylquinolin-6-ol hydrochloride; 4-[ (3-methoxyphenyl) - amino] quinolin-6,8-diol hydrochloride; and 4- (cyclohexyl¬ amino) quinolin-8-ol hydrochloride.
This invention also relates to the pharmaceutically acceptable acid addition salts and cationic salts of compounds of the formula I. Unless otherwise indicated, the term "halo", as used herein, includes fluoro, chloro, bromo and iodo.
Unless otherwise indicated, the term "alkyl", as used herein, may be straight, branched or cyclic, and may include straight and cyclic moieties as well as branched and cyclic moieties.
The compounds of formula I may have chiral centers and therefore may occur in different stereoisomeric configurations. The invention includes all stereoisomers of such compounds of formula I, including mixtures thereof. The present invention also relates to all radiolabelled forms of the compounds of the formula I. Such radiolabelled compounds are useful as research and diagnostic tools in metabolism pharmacokinetic studies and in binding assays in both animals and man. The present invention also relates to a pharmaceutical composition for enhancing or stimulating the immune response of vertebrates, including humans, cattle, swine and poultry, comprising an immune response enhancing or stimulating amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. The present invention also relates to a metϊ^od for enhancing or stimulating the immune response of verteorates, including humans, cattle, swine and poultry, comprising administering to a vertebrate an immune response enhancing or stimulating amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof.
Preferred compounds of this invention are compounds of the formula I wherein R3, R6 and R7 are hydrogen, and R4 and R5, together with the carbons to which they are attached, form a group of the formula
Figure imgf000006_0001
wherein the carbon labelled with an asterisk (*) represents the point of attachment of R4 to the quinoline nucleus and the adjacent carbon of group A represents the point of attachment of R5 to the quinoline nucleus.
Other preferred compounds of this invention are compounds of the formula I wherein R3, R4, R6 and R7 are hydrogen and R5 is amino, -NHS02Ru, -NHCOR12 or hydroxy.
Specific preferred compounds of this invention are: 9- (m-Anisidino) -7-methyl-lH-pyrazolo [3 , 4-f ] quinoline hydrochloride ;
9- (p-Cyclohexylmethoxyanilino ) -7 -methyl- 1H- pyrazolo [3 , 4-f] quinoline;
9- (Cyclohexylamino) -7-methyl-lH-pyrazolo [3,4- f] quinoline;
9- (p-Cyclohexylmethoxyanilino) -lH-pyrazolo [3,4- f] quinoline;
6-Amino-4- (p-cyclohexylmethoxyanilino) -2 - phenylquinoline ; 6-Amino-4-(p-chloroanilino) -2-phenylquinoline;
4- (p-Cyclohexylmethoxyanilino) -6-methylsulf onamido-2- pheny lquino line; 4-Decylamino-2-methylquinolin-6-ol;
4-Tetradecyl-2-methylquinolin-6-ol;
4-(Dodecylamino)quinolin-6-ol;
Other compounds of the invention are: 9-(p-Butoxyanilino)-7-methyl-lH-pyrazolo[3,4- f]quinoline;
9-(p-Chloroanilino)-7-methyl-lH-pyrazolo[3,4- f]quinoline;
9-(p-Benzyloxyanilino) -7-methyl-lH-pyrazolo[3,4- f]quinoline;
9-(p-Hydroxyanilino)-7-methyl-lH-pyrazolo[3,4- f]quinoline;
9-(m-Anisidino)-7-methyl-lH-triazolo[3,4-f]quinoline;
9-(m-Anisidino)-lH-pyrazolo[3,4-f]quinoline; 9-(p-Chloroanilino)-lH-pyrazolo[3,4-f]quinoline;
6-Amino-4-(p-butoxyanilino)-2-phenylquinoline;
6-Amino-4-(p-anisidino)-2-phenylquinoline;
4-(m-Anisidino)-2-methyl-6-(5-pyrazolo)quinoline;
4- (p-Cyclo exylmethoxyanilino) -2-methyl-6- ( 5- pyrazolo) quinoline;
9- (4-Ethylanilino) -7-methyl-lH-pyrazolo[3 , 4- f] quinoline;
7-Methyl-9- (4-propylanilino)-lH-pyrazolo[3,4- f] quinoline; 7-Methyl-9-(4-toluidino) -lH-pyrazolo [3, 4-f ] quinoline;
9-Cyclopentylamino-7-methyl-lH-pyrazolo[3 , 4- f] quinoline;
9-(4-Ethoxyanilino) -lH-pyrazolo [3, 4-f ] quinoline;
9-(4-Ethylanilino) -lH-pyrazolo[3 , 4-f ] quinoline; 9- (4-Propylamino) -lH-pyrazolo[3 , 4-f ]quinoline;
9- (4-Butylanilino) -lH-pyrazolo[3 , 4-f ]quinoline;
9- (p-Toluidino) -lH-pyrazolo [ 3 , 4-f ] quinoline ;
9-(4-Butoxyanilino) -lH-pyrazolo [3, 4-f ] quinoline;
6-Amino-4- (m-anisidino) quinoline; 6-Amino-4- (p-butoxyanilino) quinoline ;
6-Amino-4-(3,4-difluoroanilino) -2-phenylquinoline;
4- (p-Cyclohexylmethoxyanilino) -2-phenyl-6- ureidoquinoline ;
6— Acetamido -4 - (p-cyclohexylmethoxyanilino ) -2 - phenylquinoline ;
N- [4- (Cyclohexylmethyloxy) phenyl] -2-methylquinolin- , 8- diamine;
4- (4-Butylphenylamino) -2-methylquinolin-6-ol; 4- (4-Chlorophenylamino) -2-methylquinolin-6-ol ; 4- (4-Chlorophenylamino) -2-phenylquinolin-6-ol; 2-Methyl-4-octylaminoquinolin-6-ol Hydrobromide; 4- [ 4- ( Cyclohexylmethyloxy) phenylamino ] -2-methyl- quinolin-6-ol ;
4- (3-Methoxyphenylamino) -2-methylquinolin-6-ol ; 4-Hexylamino-2-methylquinolin-6-ol; 4-Dodecylamino-2-methylquinolin-6-ol; 4-[ (3-Methoxyphenyl) amino] quinolin-6-ol;
4-[ (4 -Cyclohexylmethyloxy) phenylamino ] quinolin-6-ol ; 4- (Cyclohexylamino) quinolin-6-ol; 4- (Decylamino) quinolin-6-ol;
4- (4-Butylphenyl mino) -2-methylquinolin-7-ol ; 4- [ 4- (Cyclohexylmethyloxy) phenylamino ] -2 -methyl- quinolin-7-ol ;
4- (Dodecylamino) -2-methylquinolin-7-ol; 4- (Decylamino) -2-methylquinolin-7-ol; 4- (4-Butylphenylamino) quinolin-8-ol; 4- [4- (Cyclohexylmethyloxy) phenylamino] quinolin-8-ol ;
4- (Dodecylamino) quinolin-8-ol;
4- [4- (Cyclohexylmethyloxy) phenylamino] quinolin-6 , 8- diol ; and
4- [ 4- (Cyclohexylmethyloxy) phenylamino ] quinolin-6- methanol.
Examples of other compounds of the formula I include: 7-methyl-9- (4-pyrrolidinoanilino) -lH-pyrazolo[3 , 4-f] - quinoline hydrochloride;
9- (4-aminohippuroyl) -7-methyl-lH-pyrazolo [ 3 , 4-f ] - quinoline hydrochloride;
9- (4-carboxyanilino ) -7-methyl-lH-pyrazolo [ 3 , 4 -f ] - quinoline hydrochloride; 9-(m-anisidino) -7-cyclohexyl-lH-pyrazolo[3 , 4- f] quinoline hydrochloride;
4- ( -anisidino) -6-phenylsulfonamidoquinoline hydrochloride ; 4- (m-anisidino) -7-methylsulfonamidoquinoline hydrochloride ;
4- (m-anisidino) -8-methylsulfonamidoquinoline hydrochloride ;
4- (p-ethoxyanilino) -6-guanidinoquinoline hydrochloride; 4- (p-cyclohexylmethoxyanilino) -6-guanidinoquinoline hydrochloride;
4- (p-ethoxyanilino) -7-guanidinoquinoline hydrochloride;
4- (p-cyclohexylmethoxyanilino) -7-quanidinoquinoline hydrochloride ; 4- (p-ethoxyanilino) -8-guanidinoquinoline hydrochloride;
4- (p-cyclohexylmethoxyanilino) -8-guanidinoquinoline hydrochloride ;
6-acetamidino-4- (m-anisidino) quinoline hydrochloride; 7-acetamidino-4- (m-anisidino) quinoline hydrochloride; 8-acetamidino-4- (m-anisidino) quinoline hydrochloride;
7-amino-4- (m-anisidino) quinoline hydrochloride; 4- (p-cyclohexylmethoxyanilino) -7-ureidoquinoline hydrochloride ;
4- (p-cyclohexylmethoxyanilino) -8-ureidoquinoline hydrochloride;
Detailed Description of the Invention
The reaction scheme below illustrates the synthesis of the compounds of this invention. In the reaction schemes and discussion that follow, except where otherwise stated, formula I and substituents R1 through R14 are defined as above . SCHEME
Figure imgf000010_0001
10 ir III
Figure imgf000010_0002
Figure imgf000010_0003
35 The above reaction scheme illustrates a method of preparing compounds of the formula I. For those compounds of the formula I wherein R2 is other than hydrogen, an initial condensation reaction is carried out by reacting a substituted amine of the formula II with an appropriately functionalized beta-keto ester of the formula
Figure imgf000011_0001
VI
wherein R15 is methyl or ethyl. This reaction is generally carried out in an inert solvent such as ethyl ether, a halogenated hydrocarbon, dimethylformamide (DMF) , acetonitrile or a lower alcohol, preferably ethanol, at a temperature from about ambient temperature to about the reflux temperature of the solvent, preferably from about 40°C to about 100°C. It is preferable to remove water as it is formed in the reaction using, for example, molecular sieves, sodium sulfate, magnesium or calcium sulfate (preferably calcium sulfate) , and to catalyze the reaction with a small quantity of acid (e.g., hydrochloric acid, sulfuric acid, paratoluenesulfonic acid or phosphoric acid) , preferably acetic acid.
For those compounds wherein R2 is hydrogen, the condensation reaction is carried out by reacting a alonate of the formula VII
Figure imgf000011_0002
V I I wherein each R15 is independently selected from methyl and ethyl, with an amine the formula II in an inert solvent, preferably toluene, at a temperature from about ambient temperature to about the reflux temperature of the solvent, preferable from about 20°C to about 120°C.
The compound of formula III produced in the foregoing reaction may be cyclized by heating it in a high boiling, inert solvent (e.g., xylenes, mesitylene or diphenyl ether), preferably diphenyl ether/biphenyl (Dowtherm, trademark) , at a temperature from about 140°C to about 270°C, preferably about 250°C. Where substitution of the aniline of formula II is unsymmetrical, cyclization may yield a compound of the formula IV as a mixture of isomers. These isomers may be separated by a number of purification methods well known to those skilled in the art (e.g., chromatography, crystallization, etc.)
The condensation reaction using a compound of the formula VII and the subsequent cyclization reactions described above produce compounds wherein R3 is -COOR15. These esters can be converted to the corresponding carboxylic acids, and the resulting acids decarboxylated to form the corresponding compounds wherein R3 is hydrogen. The hydrolysis reaction is typically conducted using an alkali metal hydroxide in water, a lower alcohol, tetrahydrofuran (THF) , acetonitrile or. an aqueous mixture of these solvents. It is preferably in aqueous sodium hydroxide. Suitable temperatures for this reaction range from about room temperature to about the reflux temperature of the solvent. The reflux temperature is preferred. The decarboxylation is generally carried out by heating the acid in an inert solvent (e.g., quinaldine, diphenyl ether or mesitylene), preferably in diphenyl ether/biphenyl (Dowtherm, trademark) , at a temperature from about 150°C to about 280°C, preferably about 250°C. Compounds of the formula IV wherein R2 is hydrogen are preferably prepared by condensing the appropriate aniline of formula II with 5-(alkoxymethylene)-2,2-dimethyl-1,3- dioxane-4,6-dione and then heating the so obtained 5- (anilinomethylene)-2 ,2-dimethyl-l,3-dioxane-4,6-dione at 200°C to about 270°C according to procedures described in the literature. (See McNab et aJL. , J. Chem. Soc. Perkin Trans. I. 853-868 (1988); Culbertson et al. , J. Heterocvclic Chem. , 24, 1509-1520 (1987); Matyus et al. , Heterocvcles. 20. 2225-2228 (1983); Bihlmayer et al. , Montash. Chem.. 98. 584-578 (1967); and British Patent 1,147,760 (1966) to Sterling Drug Inc.) Treatment of a compound of the formula IV with phosphorus pentachloride, phosphorus oxychloride or a mixture of the two yields the corresponding compound of formula V. The reaction temperature may range from about - 10°C to about 180°C. Preferably, the compound of formula IV is treated with phosphorus oxychloride and DMF at a temperature from about 0°C to about 75°C.
Compounds of the formula V may be converted to the corresponding compounds of formula I by reacting them with the appropriate amine of the formula HNR1 neat or in an inert solvent such as a lower alcohol, a halogenated hydrocarbon or (DMF) , preferably ethanol, at a temperature from about ambient temperature to about 180°C, depending on the reactivity of the particular amine. The preferred solvent is ethanol. Compounds of the formula I wherein R5, R6 or R7 is amino may be prepared by reduction of the corresponding compounds wherein R5, R6 or R7, respectively, is nitro using methods well known in the art. (See March, "Advanced Organic Chemistry", pp. 1125-1126, McGraw-Hill Book Company, New York, 1977) . It is preferable to use hydrogen gas at a pressure of about 1 atmosphere in the presence of palladium on carbon, and to conduct' the reaction in a. lower alcohol solvent at about room temperature.
Similarly, compounds of the formula I wherein R5 is -NHC(=NR8)R9, -NHS02Rn, -NHCOR12, guanidino or ureido, or wherein R6 is -NHCOR13, -NHC(=NR8)R9, -NHS02R13, guanidino or ureido, or wherein R7 is -NHC(=NR8)R9, -NHS02R14, -NHCOR14, ureido or guanidino, may be prepared from the corresponding amino compounds using procedures well known to those skilled in the art. (See, for the preparation of amides, March, "Advanced Organic Chemistry", pp. 392-393, McGraw-Hill Book Company, New York, 1977. See, for the preparation of sulfonamides , March, "Advanced Organic Chemistry", pp. 451- 452, McGraw-Hill Book Company, New York, 1977. See, for the preparation of amidines, March, "Advanced Organic Chemistry", pp. 823-824 and p. 891, McGraw-Hill Book Company, New York, 1977. See, for the preparation of ureas, March, "Advanced Organic Chemistry", pp. 823, McGraw-Hill Book Company, New York, 1977. See, for the preparation of guanidines, Scott et al. , J. A er. Chem. Soc, 7_5, 4053 (1953), Bannard, R.A.B. et al. , Can. J. Che (1958) and Bodansky, M. , J. Amer. Chem. S (1964) .
Compounds of the formula I wherein R5,
Figure imgf000014_0002
hydroxy or wherein R5 and R6, or R5 and R7 are both hydroxy may be prepared by treating the corresponding methoxy compounds with concentrated hydrogen bromide or hydrogen iodide or by heating them with aluminum chloride in an appropriate solvent such as toluene heated at reflux. Alternatively, the corresponding methoxy intermediates can be treated with boron tribromide or boron tribromide-methyl sulfide complex in an appropriate solvent such as methylene chloride or 1,2-dichloroethane, as exemplified below.
Figure imgf000014_0001
The resulting hydroxy compounds can then be reacted with the appropriate amines, as described above, to produce the desired compounds of structure I that are substituted in 5, 6 and/or 7 positions. Compounds of the formula I wherein R5 is 5-pyrazolyl may be prepared as described in Example 17.
Except where otherwise noted, pressure is not critical in any of the above reactions. Preferred temperatures for the above reactions were stated where known. In general, the preferred temperature for each reaction is the lowest temperature at which product will be formed.
The pharmaceutically acceptable acid addition salts of compounds of the formula I are prepared in a conventional manner by treating a solution or suspension of the free base of formula I with about one chemical equivalent of a pharmaceutically acceptable acid. Conventional concentration and recrystallization techniques are employed in isolating the salts. Examples of pharmaceutically acceptable acids are acetic, lactic, succinic, maleic, tartaric, citric, gluconic, ascorbic, benzoic, methanesulfonic, cinnamic, fumariσ, phosphonic, hydrochloric, hydrobromic, hydroiodic, sulfamic and sulfonic acid. The active compounds of this invention and their pharmaceutically acceptable acid addition salts are useful in stimulating, restoring or enhancing the immune response of a host vertebrate, thus increasing the host's resistance to infection or infestation by bacteria, viruses, fungi, etc. They are therefore useful, alone or in combination with antiinfective therapy, in the prophylactic or therapeutic treatment of any infectious disease.
The activity of the compounds of this invention as immunostimulants may be determined by the following procedure.
Mice (Harlan Sprague Dawley, female) in the control group (i.e., those not receiving drug) and those in the experimental group are infected with E. coli 51A760 (2 x 107 colony forming units) by intraperitoneal injection. (A subtherapeutic dose of gentamicin (0.5 mg/kg) may be optionally administered subcutaneously to mice in both the experimental and the control group 0.5, 4, and 24 hours after such injection) . Twenty-four hours before the injection with E. coli, the mice in the experimental group are treated subcutaneously with drug dissolved or suspended in pyrogen-free saline. The number of surviving mice in the control and experimental groups 96 hours after such infection is recorded. A compound is considered active if the number of surviving mice in the experimental group is significantly higher than those surviving in the control group. The compounds of this invention may be administered alone, but will generally be administered in admixture with a pharmaceutical carrier selected with regard to the intended route of administration and standard pharmaceutical practice. They can be injected parenterally, for example, intramuscularly, intravenously or subcutaneously. For parenteral administration, they are best used in the form of a sterile aqueous solution which can contain other solutes, for example, enough salt or glucose to make the solution isotonic. In the case of vertebrates other than humans, compounds can be administered intramuscularly or subcutaneously at dosage levels of about 0.1-50 mg/kg/day, advantageously 0.2-10 mg/kg/day given in a single daily dose or up to 3 divided doses.
The compounds of this invention can be administered to humans for the treatment of bacterial diseases by the parenteral route. For intramuscular or intravenous administration, dosage levels are about 0.1-200 mg/kg/day, advantageously 0.5-50 mg/kg/day. While intramuscular administration may consist of a single dose or up to 3 divided doses, intravenous administration can consist of a continuous drip. Variations will necessarily occur depending on the weight and condition of the subject being treated and the particular route of administration chosen, as will be known to those skilled in the art. The present invention is illustrated by the following examples. It will be understood, however, that the invention is not limited to the specific details of these exa ples. Melting points are uncorrected. Proton nuclear magnetic resonance spectra (*H NMR) and 13C nuclear magnetic resonance spectra (13C NMR) were measured for solutions in deuterodimethylsulfoxide (d6-DMSO) and peak positions are expressed in parts per million (ppm) downfield from tetramethylsilane (TMS) . The peak shapes are denoted as follows: s, singlet; d, doublet, t, triplet; q, quartet; m, multiplet; br, broad; c, complex.
EXAMPLE 1 9-(m-Anisidino)-7-methyl-lH-pyrazolo 3 ,4-f .quinoline hydrochloride
A. 9-Hydroxy-7-methy1-lH-pyrazolor3,4-f]quinoline To a suspension of 6-aminoindazole (40.0 g, 0.30 mol) in absolute ethanol (500 ml) was added ethyl acetoacetate (70.37 g, 54 mol), calcium sulfate (CaS04) (20 g) and acetic acid (2 ml) . The reaction mixture was heated to reflux and after 24 hours more calcium sulfate (10 g) and ethyl acetoacetate (19 ml) was added and the reflux continued for another 24 hour period. It was necessary to add more CaS04 (5 g) and ethyl acetoacetate (10 ml) and to reflux the reaction mixture for an additional 24 hours to complete the conversion of 6-aminoindazole to product. The solid was removed by filtration and the filtrate subjected to rotary evaporation. Ethanol was added and the slurry cooled in a refrigerator. The solid was collected by filtration, washed with hexanes and dried in a vacuum oven to give the cyclization precursor ethyl 3-(indazol-6-ylamino)but-2- enoate as a light brown solid (62.19 g, 84%).
A fraction of this material (30.00 g, 0.12 mol) was added to boiling diphenyl ether/biphenyl, (Dowtherm trademark), (i.e., a mixture of biphenyl and diphenylether) (600 ml) in portions. Upon completion of the addition, the reaction was continued for an additional 6 minutes. On cooling the reaction a precipitate formed which was collected by filtration and washed thoroughly with hexanes to give 9-hydroxy-7-methyl-lH-pyrazolo[3,4-f]quinoline as a tan solid (23 g, 94%) . :H NMR: δ 2.40 (s, 3H) , 6.10 (s, 1H) , 7.22 (d, 1H, J=8) , 7.84 (d, 1H, J=8), 8.08 (s, 1H) .
B. 9-Chloro-7-methyl-lH-pyrazolo[3r4-f.quinoline To a suspension of 9-hydroxy-7-methyl-lH-pyrazolo[3,4- f]quinoline (8.00 g, 0.04 mmol) in phosphorus oxyc loride (61.6 g, 0.40 mol) was added slowly N,N-dimethylformamide (40 ml) . After the addition was complete, the reaction mixture was warmed to 80°C for 1 hour and then allowed to cool to room temperature. The reaction was poured onto ice and dissolved in water (2 L total volume) and neutralized to pH 7 with 20% sodium hydroxide (NaOH) . The precipitate which formed upon neutralization was collected by filtration, washed with water and dried under vacuum to give 9-chloro-7-methyl-lH-pyrazolo[3, -f]quinoline as a white solid (8.07 g, 92%).
*H NMR: δ 2.66 (s, 3H) , 7.61 (d, 1H, J=9) , 7.72 (s, 1H) , 8.07 (d, 1H, J=9) , 8.33 (s, 1H) .
C. 9 - (m-Anis idino ) -7 -methyl-lH-pyraz olo [ 3 , 4- f] quinoline hydrochloride To a solution of 9-chloro-7-methyl-lH-pyrazolo[3 , 4- f] quinoline (1.63 g, 7.5 mmol) in ethanol (60 ml) was added m-anisidine (1.11 g, 9.0 mmol) and the mixture was heated at reflux overnight. T: 3 solvent was removed by rotary evaporation and the residue redissolved in methanol and treated with decolorizing carbon. After filtration through diatomaceous earth (Celite™) , the filtrate was subjected to rotary evaporation and the resulting pale yellow solid recrystallized from methanol/ ethyl ether to give 9- (m- anis idino ) -7 -methyl - lH-pyra z o l o [ 3 , 4 -f ] qu ino l ine hydrochloride (2.35 g, 92%) as pale yellow needles.
'H NMR: δ 2.72 (s, 3H) , 3.85 (s, 3H) , 7.05 (d, 1H, J=8) , 7.12 (s, 1H) , 7. 14-7.18 (m, 2H) , 7.50 (t, 1H, J=8) , 7.72 (d, 1H, J=9) , 8.34 (d, 1H, J=9) , 8.84 (s, 1H) . M. S. : m/e 304 (M+, 100) .
Analysis: Calc'd for C18HI6N40«HC1»1.5H20: C, 58.78 ; H, 5.48 ; N, 15.23%. Found: C, 59.19; H, 5.51; N, 14.96%. The title compound of Examples 2-6 were prepared by reaction of 9-chloro-7-methyl-lH-pyrazolo[3,4-f]quinoline with the requisite aniline derivative according to the procedure described in Example 1. EXAMPLE 2
9-(p-Cyclohexylmethoxyanilino)-7-methyl-lH-pyrazolo[3,4- f]quinoline hydrochloride lH NMR: δ 1.1-1.4 ( , _5H) , 1.7-2.0 (m, 6H) , 2.64 (s, 3H) , 3.83 (d, 2H, J=6) , 6.86 (s, IH) , 7.10 (d, 2H, J=9) , 7.45 (d, 2H, J=9) , 7.69 (d, IH, J=9), 8.30 (d, IH, J=9),8.83 (s, IH).
M.S. : m/e 386 (M+, 40) .
High Resolution Mass Spectrum: Calc'd for C24H26N40: 386.2107 Found: 386.2077. EXAMPLE 3
9- (p-Butoxyanilino) -7-methyl-lH-pyrazolo [ 3 , 4-f ] quinoline hydrochloride
'H NMR: δ 0.96 (t, 3H, J=6) , 1.46 (m, 2H) , 1.72 (m, 2H) , 2.66 (S, 3H) , 4.04 (t, 2H, J=6) , 6.86 (s, IH) , 7.11 (d, 2H, J=9), 7.46 (d, 2H, J=9) , 7.70 (d, IH, J=8) , 8.30 (d, IH, J=8), 8.82 (Ξ, IH) .
M.S. : m/e 346 (M+, 90) .
EXAMPLE 4 9- (p-Chloroanilino) -7-methyl-lH-pyrazolo[3 , 4-f ]quinoline hydrochloride
'H NMR: δ 2.68 (s, 3H) , 7.06 (s, IH) , 7.62 (m, 4H) , 7.68 (d, IH, J=9) , 8.28 (d, IH, J=9) , 8.80 (s, IH) . M.S. : m/e 309 (M+, 100) .
Analysis: Calc'd for C17H13N4C1»HC1»H20: C, 56.21; H, 4.44; N, 15.42%. Found: C, 56.21; H, 4.40; N, 15.24%. EXAMPLE 5 9-fp-Benzyloxyanilino)-7-methyl-lH-pyrazolor3,4- f1quinoline hydrochloride
2H NMR: £ 2.64 (s, 3H) , 5.18 (s, 2H) , 6.86 (s, IH) , 7.19 (d, 2H, J=8), 7.3-7.5 (m, 7H) , 7.65 (d, IH, J=10) , 8.28 (d, IH, J=10) , 8.80 (S, IH) .
M.S. : m/e 380 (M+, 25) .
Analysis (free base) : Calc'd for C24H20N4Oβ0.5H2O: C, 74.02; H, 5.44; N, 14.39%. Found: C, 74.32; H, 5.08; 14.26%.
EXAMPLE 6 9-(p-Hydroxyanilino) -7-methyl-lH-pyrazolor3.4-f) quinoline hydrochloride
XH NMR: S 2.66 (s, 3H) , 6.84 (s, IH) , 6.96 (d, 2H, J=8) , 7.34 (d, 2H, J=8) , 7.66 (d, IH, J=10) , 8.30 (d, IH, J=10) , 8.82 (s, IH) .
M.S.: m/e 290(M+, 100).
Analysis: Calc'd for C H14N40«HCl: C, 62.48; H, 4.63; N, 17.14%. Found: C, 61.91; H, 4.43; N, 16.93%. EXAMPLE 7
9-(Cyclohexylamino)-7-methyl-lH-pyrazolo.3,4-f]quinoline hydrochloride
9-Chloro-7-methyl-lH-pyrazolo[3,4-f]quinoline (0.44 g,
2.0 mmol) and cyclohexylamine (0.79 g, 8.0 mmol) were placed in a sealable reaction vessel which was flushed with nitrogen and then sealed. The reaction was placed in a
175°C bath and heated overnight. The excess cyclohexylamine was removed by rotary evaporation and the residue dissolved in methanol and treated with decolorizing carbon. After filtration through diatomaceous earth (Celite™) , the methanol was removed by rotary evaporation and the residue partitioned between ethyl acetate and aqueous potassium hydroxide (KOH) . The organic layer was washed with water and dried over sodium sulfate (Na2S04) , and the solvent was removed by rotary evaporation to give a white solid. The solid was washed with ether giving 9-(cyclohexylamino)-7- ethyl-lH-pyrazolo[3,4-f]quinoline as white needles (0.38 g, 68%) . The free base was converted to the corresponding hydrochloride salt by treatment with anhydrous hydrogen chloride (HCl)/ether.
JH NMR: δ 1.3 - 2.2 (m, 10H) , 2.74 (s, 3H) , 4.0 (br s, IH) , 7.12 (S, IH) , 7.64 (d, IH, J=8) , 8.26 (d, IH, J=8), 8.80 (S, IH) , 9.41 (d, IH, J=6) . M.S. : m/e 280(M+, 55) .
Analysis: Calc'd for CπH20N4»HCl: C, 64.45; H, 6.68; N, 17.68%. Found: C, 63.98; H, 6.46; N, 17.43%. EXAMPLE 8
9-(m-Anisidino)-7-methyl-lH-triazolo[3 ,4-f]quinoline hydrochloride
The title compound was prepared by the method described in Example 1 with the modification that 5-aminobenzotriazole was used as the starting material instead of 6- aminoindazole.
JH NMR: δ 2.76 (s, 3H) , 4.85 (s, 3H) , 7.00 (d, IH, J=8) , 7.20 (apparent s, 3H) , 7.50 (t, IH, J=8) , 8.19 (d, IH, J=9) , 8.44 (d, IH, J=9) . High resolution Mass Spectrum: Calc'd for C17H15N50: 305.1277. Found: 305.1278.
EXAMPLE 9 9-(m-Anisidino)-lH-pyrazolo[3,4-f]quinoline hydrochloride A. Ethyl 3-N-(6-indazolyl)amino-2-ethoxycarbonyl-2- propenoate
6-Aminoindazole (10.00 g, 75 mmol) was suspended in toluene (150 ml) to which diethyl ethoxymethylene alonate
(19.45 g, 90 mmol) was then added and the reaction mixture was heated to reflux. After 3 hours the heat was removed and the reaction mixture was stirred at room temperature overnight. The solvent was removed by rotary evaporation and the residue triturated with hexanes. The tan solid was collected by filtration, washed with hexanes and air dried to give the expected product ethyl 3-N-(6-indazolyl)amino-2- ethoxycarbony1-2-propenoate (19.26 g, 85%). *H NMR: δ 1.2 (overlapping t, 6H) , 4.15 (overlapping q, 4H) , 7.08 (d, IH, J=6), 7.42 (s, IH) , 7.70 (d, IH, J=6) , 7.98 (s, IH) , 8.42 (overlapping s, 2H) .
B. 8-Carboxy-9-hvdroxy-lH-pyrazolor3,4-f1quinoline To boiling diphenyl ether/biphenyl, (Dowtherm, trademark), (320 ml) was added ethyl 3-N-(6-indazolyl)amino- 2-ethoxycarbony1-2-propenoate (17.26 g, 57 mmol) portionwise. After the addition was complete the reaction was continued for an additional 15 minutes and then allowed to cool to room temperature. The precipitate which formed upon cooling was collected by filtration and washed thoroughly with hexanes to give 8-carboethoxy-9-hydroxy-lH- pyrazolo[3,4-f]quinoline as a light brown powder (13.31 g, 91%) . A mixture of 8-carboethoxy-9-hydroxy-lH-pyrazolo[3,4- f]quinoline (12.31 g, 47.8 mmol) and 10% aqueous sodium hydroxide (96 ml) was refluxed for 8 hours, at which time the dark-colored solution was treated with decolorizing carbon and filtered through diatomaceous earth (Celite™) . The filtrate was neutralized with 6M HCl and the resulting precipitate isolated by filtration. The light brown solid was air dried to give 8-carboxy-9-hydroxy-lH-pyrazolo[3,4- f]quinoline (10.08 g, 92%).
JH NMR: δ 7.48 (d, IH, J=8) , 8.19 (d, IH, J=8) , 8.26 (s, IH) , 8.90 (s, IH) .
C. 9-Hydroxy-lH-pyrazolor3.4-f1quinoline
A mixture of 8-carboxy-9-hydroxy-lH-pyrazolo[3,4- f]quinoline (5.00 g, 21.8 mmol) and quinaldine (50 ml) were refluxed for 20 hours. After cooling, the precipitate was collected by filtration and washed thoroughly with ether to give 9-hydroxy-lH-pyrazolo[3,4-f]quinoline (2.97 g, 74%). H NMR: δ 6.24 (d, IH, J=7) 7.24 (d, IH, J=9) , 7.96 (m, 2H) r 8.10 (s, IH) .
D. 9-Chloro-lH-pyrazolo[3 ,4-f]quinoline A mixture of 9-hydroxy-lH-pyrazolo[3,4-f]quinoline
(2.97 g, 16.0 mmol) and phosphorus oxychloride (24.58 g, 160 mmol) at 0°C was treated with dimethylformamide (DMF) (15.4 ml) dropwise. After addition was complete, the viscous reaction mixture was allowed to warm to room temperature and stirred overnight. The mixture was then poured onto ice and the resulting dark brown solution was treated with decolorizing carbon and filtered, and the brown filtrate neutralized with 10M NaOH. The light brown solid which resulted was collected by filtration and air dried giving 9- chloro-lH-pyrazolo[3,4-f]quinoline (1.73 g, 53%).
'H NMR: δ 7.65 (d, IH, J=9) , 7.76 (d, IH, J=5) , 8.08 (d, IH, J=9), 8.34 (S, IH) , 8.78 (d, IH, J=5) .
E. 9- (m-Anisidino) -lH-pyrazolo[3 , 4-f]quinoline hydrochloride
To a suspension of 9-chloro-lH-pyrazolo[3,4-f]quinoline
(1.10 g, 5.4 mmol) in absolute ethanol (50 ml) was added - anisidine (0.79 ml, 7.1 mmol) and the reaction mixture heated at reflux for 48 hours. The solvent was removed by rotary evaporation and the residue was dissolved in boiling methanol, treated with decolorizing carbon and filtered to give a light yellow solution. The solvent was removed by rotary evaporation and the residue was recrystallized from methanol/ether to give 9-(m-anisidino)-lH-pyrazolo[3,4- f]quinoline hydrochloride (1.04 g, 59%) as off-white crystals.
!H NMR: £ 3.86 (s, 3H) , 6.98 (d, IH, J=6) , 7.16 (m, 2H) , 7.22 (d, IH, J=6) , 7.48 (t, IH, J=6) , 7.68 (d, IH, J=9) , 8.30 (d, IH, J=9) , 8.50 (d, IH, J=6) , 8.84 (s, IH) . M.S. : m/e 290(M+, 100) .
Analysis (mesylate salt) : Calc'd for C14H14N40«CH3S03H: C, 55.55; H, 4.57; N, 14.16%. Found: C, 55.95; H, 4.70; N, 14.50%.
The title compound of Examples 10 and 11 were prepared by reaction of 9-chloro-lH^pyrazolo[3,4-f]quinoline with the requisite aniline derivative according to the procedure described in Example 9. EXAMPLE 10 9-(p-Cyclohexylmethoxyanilino)-lH-pyrazolor3 ,4-f]quinoline hydrochloride
XH NMRϊ δ 0.9 - 1.3 (m, 5H) , 1.6 - 1.9 (m, 6H) , 4.82 (d, 2H, J=6) , 6.94 (br s, IH) , 7.08 (d, 2H, J=7) , 7.44 (d, 2H, J=7), 7.68 (br s, IH) , 8.30 (d, IH, J=8) , 8.46 (br s, IH) , 8.82 (br s, IH) .
M.S. : m/e 371 (M+, 30) .
EXAMPLE 11 9-(p-Chloroanilino) -lH-pyrazolo[3 ,4-f]quinoline hydrochloride
*H NMR: δ 7.18 (d, IH, J=7) , 7.6 - 7.7 (m, 5H) , 8.37 (d, IH, J=9) , 8.54 (d, IH, J=7) , 8.87 (s, IH) . M.S.: m/e 294 (M+, 100). EXAMPLE 12
6-Amino-4-(p-butoxyanilino)-2-phenylquinoline hydrochloride
A. 4-Chloro-6-nitro-2-phenylquinoline 4-Hydroxy-6-nitro-2-phenylquinoline (10.00 g, 38 mmol) was suspended in phosphorus oxychloride (P0C13) (57.58 g, 380 mmol) at 0°C. Dimethyl ormamide (DMF) (45 ml) was added dropwise and the resulting mixture heated at 70°C for 5 hours. The reaction was cooled and then poured onto ice. The pH was adjusted to 6 with aqueous sodium hydroxide and the precipitate collected by vacuum filtration and dried in a vacuum oven to give 4-chloro-6-nitro-2-phenylquinoline (10.95 g, 102%) as a yellow powder. M.P.: 166-167°C.
XH NMR: δ 7.5 - 7.6 (m, 3H) , 8.3 - 8.4 (m, 3H) , 8.52 (s, IH) , 8.61 (dd, IH, J=9, 3), 9.10 (d, IH, J=3) .
B. 4-(p-Butoxyanilino)-6-nitro-2-phenylquinoline
To a suspension of 4-chloro-6-nitro-2-phenylquinoline
(0.57 g, 2.0 mmol) in absolute ethanol (25 ml) was added 4- butoxyaniline (0.40 g, 2.4 mmol) , and the mixture was heated at reflux for 4 hours. The solvent was removed by rotary evaporation and the residue was redissolved in methanol, treated with decolorizing carbon and filtered through diatomaceous earth (Celite™) . The solvent was removed by rotary evaporation. The residue was recrystallized from methanol/ether to give 4- (p-butoxy) -6-nitro-2- phenylquinoline (0.61 g, 69%). •H NMR: δ 1.00 (t, 3H, J=6) , 1.5 (m, 2H) , 1.75 (m, 2H) , 4.08 (t, 2H, J=6) , 7.00 (s, IH) , 7.18 (d, 2H, J=9) , 7.50 (d, 2H, J=9), 7.63 (m, 3H) , 7.96 (d, 2H, J=6) , 8.54 (d, IH, J=8) , 8.76 (d, IH, J=8), 9.84 (s, IH) .
C. 6-Amino-4- (p-butoxyanilino) -2-phenylquinoline hydrochloride
To a suspension of 4-(p-butoxy) -6-nitro-2- phenylquinoline (0.42 g, 0.94 mmol) in methanol (25 ml) was added ammonium formate (0.59 g, 9.4 mmol) and, finally, 10% palladium on carbon (Pd/C) (50 mg) , and the mixture heated at reflux for 1.5 hours. The reaction was filtered warm through diatomaceous earth (Celite™) and the solvent was removed by rotary evaporation. The remaining solid was washed thoroughly with water and then recrystallized from methanol/ether. The resulting yellow crystals (0.16 g, 40%) were dissolved in methanol (10 ml) and treated with HCl in ether (1M, 8 ml) . The solvent was removed and the residue recrystallized twice from methanol/ether to give 6-amino-4- (p-butoxyanilino) -2-phenylquinoline hydrochloride (0.08 g, 48%) as a yellow solid. 'H NME: δ 1.00 (t, 3H, J=6) , 1.48 (m, 2H) , 1.76 (m, 2H) , 4.06 (t, 2H, J=5) , 6.76 (s, IH) , 7.12 (d, 2H, J=9) , 7.44 (d, 2H, J=9) , 7.52 (d, IH, J=6) , 7.6 - 7.7 (m, 4H) , 7.84 (d, 2H, J=6) , 8.16 (d, IH, J=9) .
M.S. : m/e 383 (M+, 70) . Analysis: Calc'd for C25H25N30«2HC1*H20: C, 63.29; H, 6.16; N, 8.86%. Found: C, 62.91; H, 6.36; N, 8.63%.
The title compounds of Examples 13-15 were prepared by reaction of 4-chloro-6-nitro-2-phenylquinoline with the requisite aniline derivative according to the procedure described in Example 12. EXAMPLE 13 6-Amino-4- (p-cyclohexylmethoxyanilino) -2-phenylquinoline hydrochloride
*H NMR: δ 1.1 - 1.2 (m, 5H) , 1.6 - 1.8 (m, 6H) , 3.81 (d, 2H, J=6) , 6.70 (S, IH) , 7.07 (d, 2H, J=9) , 7.4 - 7.5 (m, 3H) , 7.5 - 7.6 (m, 4H) , 7.78 (d, 2H, J=8) , 8.07 (d, IH, J=9) , 10.31 (s, IH) .
M.S. : m/e 423 (M+, 60) .
Analysis: Calc'd for C2gH29N3O*2HCl«0.5H2O: C, 66.53; H, 6.38; N, 8.31%. Found: C, 66.54; H, 5.93; N, 8.0%.
EXAMPLE 14 6-Amino-4- (p-chloroanilino) -2-phenylquinoline hydrochloride
XH NMR: δ 6.94 (s, IH) 7.5 - 7.6 (m, 9H) , 7.86 (d, 2H, J=6) , 8.14 (d, IH, J=9), 10.44 (s, IH) . M.S.: m/e 345 (M+, 100).
Analysis: Calc'd for C21HI6N3C1«2H20«1.5HC1: C, 57.32; H, 4.49; N, 9.40%. Found: C, 57.78; H, 4.96; N, 9.63%.
EXAMPLE 15 6-Amino-4-(p-anisidino) -2-phenylquinoline hydrochloride
XH NMR: δ 3.80 (s, 3H) , 7.08 (d, 2H, J=8) , 7.43 (d, 2H, J=8) , 7.5 - 7.8 (m, 7H) , 8.13 (d, IH, J=9) , 10.42 (s, IH) . M.S.: m/e 341 (M+, 100).
Analysis: Calc'd for C22H19N30«2HC1»1.5H20: C, 59.87; H, 5.48; N, 9.08%. Found: C, 59.66; H, 5.44; N, 9.52%.
EXAMPLE 16 4-(p-Cvclohexylmethoxyanilino)-6-methylsulfonamido-2- phenylquinoline hydrochloride
To a suspension of 6 -amino -4 - (p - cyclohexylmethoxyanilino)-2-phenylquinoline hydrochloride
(0.21 g, 0.5 mmol) in anhydrous THF (10 ml) at 0°C was added methanesulfonyl chloride (69 mg, 0.6 mmol) followed by
• addition of triethylamine (61 mg, 0.6 mmol). The reaction. mixture was allowed to warm slowly to room temperature and stirred overnight. The solvent was removed by rotary evaporation and the residue partitioned between ethyl acetate (EtOAc) and 1M hydrochloric acid. The layers were separated, the organic layer was washed with saturated sodium bicarbonate and dried (Na2S04) and the solvent was removed by rotary evaporation. The crude material was dissolved in warm methanol and treated with 1M HCl in ether. After 2 hours at room temperature, the solvent was removed by rotary evaporation and the residue recrystallized from methanol/ether to give 4-(p-cyclohexylmethoxyanilino)-6- methylsulfonamido-2-phenylquinoline hydrochloride (38%) as a pale yellow solid. JH NMR: δ 0.9 - 1.3 (m, 5H) , 1.6 - 1.8 (m, 6H) , 3.24 (s, 3H) , 3.82 (d, 2H, J=6) , 6.78 (s, IH) , 7.09 (d, 2H, J=9) , 7.44 (d, 2H, J=9) , 7.6 ( , 3H) , 7.83 (m, 3H) , 8.34 (m, 2H) . M.S. : m/e 502(M+, 10) .
EXAMPLE 17 4-(m-Anisidino)-2-methyl-6-(5-pyrazolo)quinoline hydrochloride
A. 4-Nitrobenzoylacetaldehyde
To a solution of 4-nitroacetophenone (8.26 g, 50 mmol) in anhydrous tetrahydrofuran (THF) at 0°C was slowly added sodium ethoxide in ethanol (prepared from 1.27 g (55 mmol) sodium in 26 ml ethanol) followed by addition of ethyl formate (5.56 g, 75 mmol). The reaction was allowed to slowly warm to room temperature and stir overnight. The reaction was diluted with water (800 ml) and washed with ether. The aqueous layer was acidified (pH 1-2) with concentrated hydrochloric acid (HCl) and the mixture extracted with ethyl acetate. The combined organic layers were dried (Na2S04) and the solvent was removed by rotary evaporation to give 4-nitrobenzoylacetaldehyde (2.69 g, 28%) as an orange solid.
JH NMR (CDC13) : δ 6.24 (d, IH, J=3), 8.02 (d, 2H, J=9) , 8.28 (d, 2H, J=9) , 8.44 (d, IH, J=3) .
B. 4-(5-Pyrazoyl)nitrobenzene
To a suspension of 4-nitrobenzoylacetaldehyde (2.75 g, 14.2 mmol) in methanol (100 ml) at 0°C was added hydrazine hydrate (0.50 g, 15.7 mmol) . The resulting burgundy solution was stirred at 0°C for 2.5 hours, at which time the solvent was removed by rotary evaporation and the residue was partitioned between water and ethyl acetate. The aqueous layer was extracted with more ethyl acetate and the combined organics were then washed with saturated sodium chloride (NaCl) and dried (Na2S04) , and the solvent was removed by rotary evaporation to give 4-(5- pyrazoyl)nitrobenzene (2.32 g, 86%) as an orange solid.
XH NMR: δ 6.90 (s, IH) , 7.84 (s, IH) , 8.04 (d, 2H, J=9) , 8.22 (d, 2H, J=9) . C. 4-Hydroxy-2-methyl-6-(5-pyrazolyl)quinoline
To a suspension of 4-(5-pyrazoyl)nitrobenzene (1.25 g, 6.6 mmol) in methanol (60 ml) was added 10% Pd/C (0.13 g) and the mixture shaken under hydrogen (45 psi) for 2 hours. The reaction was filtered through diatomaceous earth (Celite™) and the solvent was removed by rotary evaporation to give 4-(5-pyrazoyl)aniline as a brown oil which was used directly in the next reaction.
To a solution of 4-(5-pyrazoyl)aniline (1.05 g, 6.6 mmol) in absolute ethanol (20 ml) was added ethyl acetoacetate (1.72 g, 13.2 mmol), calcium sulfate (2.0 g) and a few drops of acetic acid, and the mixture was heated at reflux for 48 hours, with more calcium sulfate (2.0 g) and ethyl acetoacetate (0.85 g) added after 12 and 36 hours. The reaction was then cooled to room temperature, filtered, and the solvent was removed by rotary evaporation. The residue was triturated with several portions of methanol, the methanol fractions were combined and the solvent was removed by rotary evaporation. The residue was chro atographed (silica gel, 20% ethyl acetate (EtOAc) in methylene chloride (CH2C12) to 5% methanol (CH3OH) in EtOAc) to give the condensation product as a yellow oil (0.11 g, 7%) . This was cyclized by adding it portionwise to boiling diphenyl ether/biphenyl, (Dowtherm, trademark) , (10 ml) . After the addition was complete, the reaction was continued for an additional 10 minutes and then allowed to cool to room temperature. The precipitate which formed was collected by filtration, washed well with hexanes and dried under vacuum to give 4-hydroxy-2-methyl-6-(5- pyrazoyl)quinoline (63%) as a brown solid.
]HNMR: £ 2.32 (s, 3H) , 5.90 (s, IH) , 6.72 (s, IH) , 7.50 (d, IH, J=7) , 7.78 (s, IH) , 8.06 (d, IH, J=7) , 8.38 (s, IH) . M.S.: m/e 225 (M+, 100).
D. 4-Chloro-2-methyl-6-(5-pyrazoyl)quinoline
To a suspension of 4-hydroxy-2-methyl-6-(5- pyrazoyl)quinoline (0.13 g, 0.55 mmol) in phosphorus oxychloride (0.85 g, 5.5 mmol) cooled in a water bath was added DMF (5 ml) dropwise and the reaction mixture was stirred at room temperature overnight. The reaction mixture was poured onto ice and the solution neutralized with ION NaOH. The precipitate which formed was filtered, washed with water and dried under vacuum to give 4-chloro-2-methyl- 6-(5-pyrazoyl)quinoline (0.12 g, 86%) as light brown solid. lH NMR: δ 2.66 (s, 3H) , 6.86 (s, IH) , 7.70 (s, IH) , 7.84
(S, IH) , 8.00 (d, IH, J=8) , 8.28 (d, IH, J=8) , 8.50 (s, IH) .
E. 4-(m-Anisidino)-2-methyl-6-(5-pyrazoyl)quinoline hydrochloride To a solution of 4-chloro-2-methyl-6-(5- pyrazoyl)quinoline (0.10 g, 0.41 mmol) in absolute ethanol (7.5 ml) was added m-anisidine (61 mg, 0.49 mmol) and the reaction was refluxed overnight. The solvent was removed by rotary evaporation. The residue was redissolved in methanol, treated with decolorizing carbon and filtered through diatomaceous earth (Celite™) . The solvent was then removed by rotary evaporation. The crude product was recrystallized from methanol/ether to give 4-(m-anisidino)- 2-methyl-6-(5-pyrazoyl)quinoline hydrochloride (92 mg, 61%) as yellow needles. tø NMR: £ 2.60 (S, 3H) , 3.81 (s, 3H) , 6.74 (s, IH) , 6.98 (d, IH, J=8) , 7.05 (m, 3H) , 1. Al (t, IH, J=8) , 7.86 (s, IH) , • 8.05 (d, IH, J=8), 8.46 (d, IH, J=8) , 9.16 (s, IH) . M.S. : m/e 330 (M+, 100) . Analysis : Calc'd for C20H18N4O«HCl* 0. 25H20: C , 64 . 69 ; H,
5.29 ; N, 15 . 09% . Found : C, 64 . 58 ; H, 5 . 01 ; N, 15. 10% . EXAMPLE 18 4-f -Cyclohexylmethoxyanilino)-2-methyl-6-(5- pyrazolo) uinoline hydrochloride
4-Chloro-2-methyl-6-(5-pyrazoyl)quinoline was treated with p-cyclohexylmethoxyaniline using the procedure described in Example 17 to give 4-(p- cyclohexylmethoxyanilino)-2-methyl-6-(5-pyrazolo)quinoline hydrochloride.
*H NMR: £ 1.0 - 1.3 (m, 5H) , 1.6 - 1.9 (m, 6H) , 2.48 (s, 3H) , 3.84 (d, 2H, J=6) , 6.52 (s, IH) , 7.02 (s, IH) , 7.08 (d, 2H, J=9) , 7.36 (d, 2H, J=9) , 7.86 (br s, IH) , 7.98 (d, IH, J=7) , 8.42 (d, IH, J=7) , 9.10 (s, IH) . M.S.: m/e 412 (M+, 15).
High Resolution Mass Spectrum: Calc'd for C^H^N,,©: 412.2263. Found: 412.2243.
The following compounds were prepared by a procedure similar to that of Example 6.
EXAMPLE 19 9- f 4-Ethylanilino) -7-methyl-lH-pyrazolo[3 , 4-f ]quinoline mesylate
*H NMR: £ 1.24 (t, 3H, J=7) , 2.6 - 2.7 (m, 5H) , 7.04 (s, IH) , 7.42 (d, 2H, J=8) , 7.48 (d, 2H, J=8) , 7.53 (d, IH, J=9) , 8.34 (d, IH, J=9), 8.86 (s, IH) . M.S. : m/e 302 (M+, 95) . Analysis: Calc'd for C19HI8N4»CH3SO3H*0.75H2O: C, 58.31; H,
5.75; N, 13.60%. Found: C, 58.30; H, 5.37; N, 16.21%.
EXAMPLE 20 7-Methyl-9- (4-propylanilino) -lH-pyrazolo [3 ,4- f] quinoline hydrochloride XH NMR: £ 0.93 (t, 3H, J=7) , 1.64 (m, 2H) , 2.53 (m, 5H) ,
7.02 (s, IH) , 7.39 (d, 2H, J=8) , 7.47 (d, 2H, J=8) , 7.70 (d, IH, J=9) , 8.31 (d, IH, J=9) , 8.83 (s, IH) . M.S. : m/e 316 (M+, 70) .
Analysis: Calc'd for C,oH20N4«HCl*H20: C, 64.77; H, 6.25; N, 15.11%. Found: C, 64.43; H, 6.03; N, 14.89%. EXAMPLE 21 7-Methyl-9- (4-toluidino) -lH-pyrazolo.3 , 4-f Iquinoline hydrochloride
*H NMR: £ 2.42 (s, 3H) , 2.70 (s, 3H) , 7.01 (s, IH) , 7.41 (d, 2H, J=8), 7.44 (d, 2H, J=8) , 7.72 (d, IH, J=9) , 8.34 (d, IH, J=9) , 8.86 (s, IH) .
M.S. : m/e 288 (M+, 100) .
Analysis: Calc'd for C18H16N4*HC1«H20: C, 63.06; H, 5.59; N, 16.34%. Found: C, 62.90; H, 5.37; N, 16.21%. EXAMPLE 22
9-Cyclopentylamino-7-methyl-lH-pyrazolor3 ,4-f]quinoline mesylate
The title compound was prepared as described for Example 7 except that cyclopentylamine was used instead of cyclohexylamine.
!H NMR: £ 2.6 - 2.8 (m, 6H) , 2.2 (m, 2H) , 2.32 (s, 3H) , 2.68 (s, 3H) , 4.34 (m, IH) , 7.04 (s, IH) , 7.44 (d, IH, J=9) , 8.24 (d, IH, J=9) , 8.78 (s, IH) . M.S. : m/e 266 (M+, 95) . Analysis: Calc'd for C16H,gN4»CH3SO3H*0.25H2O: C, 55.66; H, 6.18; N, 15.27%. Found: C, 55.53; H, 5.96; N, 15.20%.
The title compounds of Examples 23-28 were prepared by a procedure similar to that described in Example 1.
EXAMPLE 23 9-(4-Ethoxyanilino) -lH-pyrazolo[3 , 4-f]q inoline mesylate
Η NMR: £ 1.38 (t, 3H, J=6) , 2.32 (s, 3H) , 4.12 (q, 2H, J=6) , 7.00 (d, IH, J=6) , 7.14 (d, 2H, J=8) , 7.50 (d, 2H, J=8), 7.58 (d, IH, J=9) , 8.36 (d, IH, J=9) , 8.50 (d, IH, J=6), 8.88 (s, IH) .
M.S. : m/e 304 (M+, 95) .
EXAMPLE 24
9-(4-Ethylanilino)-lH-pyrazolo[3 ,4-f] uinoline mesylate
!H NMR: £ 1.24 (t, 3H, J=7) , 2.34 (s, 3H) , 2.70 (q, 2H, J=7) , 7.14 (d, IH, 3=1), 7.42 (d, 2H, J=7) , 7.48 (d, 2H,
J=7) , 7.56 (d, IH, J=9) , 8.36 (d, IH, J=9) , 8.50 (d, IH,
J=6) , 8.88 (s, IH) . M.S.: m/e 288 (M+, 95) .
Analysis: Calc'd for C18HlβN4» CH3S03H« 1.25H20: C, 56.08; H, 5.57; N, 13.77%. Found: C, 55.72; H, 4.89; N, 13.57%.
EXAMPLE 25 9-(4-Propylamino) -lH-pyrazolo[3.4-f 1 quinoline mesylate
'H NMR: £ 0.94 (t, 3H, J=7) , 1.62 (m, 2H) , 2.36 (s, 3H) , 2.64 (t, 2H, J=7), 7.12 (d, IH, J=8) , 7.40 (d, 2H, J=6) , 7.48 (d, 2H, J=6) , 7.56 (d, IH, J=9) , 8.36 (d, IH, J=9) , 8.50 (br d, IH) , 8.88 (s, IH) . M.S.: m/e 302 (M+, 80).
Analysis: Calc'd for CI9HlgN4*CH3SO3H«0.5H2O: C, 58.95; H, 5.69; N, 13.75%. Found: C, 59.15; H, 5.32; N, 13.63%.
EXAMPLE 26 9- (4-Butylanilino) -lH-pyrazolo T3 , 4-f ] quinoline mesylate XH NMR: £ 0.96 (t, 3H, J=6) , 1.35 (m, 2 . , 1.62 (m, 2H) ,
2.36 (s, 3H) , 2.68 (t, 2H, J=6) , 7.16 (d, IH, J=7) , 7.44 (d, 2H, J=7) , 7.50 (d, 2H, J=7) , 7.60 (d, IH, J=9) , 8.40 (d, IH, J=9), 8.54 (br d, IH, J=7), 8.92 (s, IH) . M.S. : m/e 316 (M+, 70) . EXAMPLE 27
9-(p-Toluidino) -!H-pyrazolor3 , 4 -fl quinoline hydrochloride
XH NMR: £ 2.40 (s, 3H) , 7.08 (d, 2H, J=7) , 7.38 (d, 2H, J=7), 7.46 (d, 2H, J=7) , 7.70 (d, IH, J=9) , 8.34 (d, IH, J=9), 8.48 (d, IH, J=7) , 8.86 (s, IH) . M.S.: m/e 274 (M+, 100).
Analysis: Calc'd for C17Hι4N4»CH3S03H«1.25H20: C, 55.02; H, 5.26; N, 14.26%. Found: C, 55.15; H, 5.01; N, 14.13%.
EXAMPLE 28 9- f 4-Butoxyanilino) -lH-pyrazolo T3 , 4-f 1 quinoline hydrochloride
XH NMR: £ 0.94 (t, 3H, J=6) \ 1.42 (m, 2H) , 1.70 (m, 2H) , 4.02 (t, 2H, J=5) , 6.94 (s, IH, J=7) , 7.10 (d, IH, J=8) , 7.44 (d, 2H, J=8), 7.66 (d, IH, J=9) , 8.32 (d, IH, J=9) , 8.44 (d, IH, J=7) , 8.84 (s, IH) . M.S.: m/e 332 (M+, 100) . EXAMPLE 29 6-Amino-4-(m-anisidino)quinoline hydrochloride The title compound was prepared from the corresponding 6-nitro compound by catalytic reduction of the nitro group followed by treatment with HCl in ether. The 6-nitro-4-(m- anisidino)quinoline compound was prepared in an analogous fashion to Example 9 with the modification that 4- nitroaniline was used as the starting material instead of 6- aminoindazole. !H NMR: £ 3.79 (s, 3H) , 6.78 (d, 2H, J=7) , 6.9 - 7.0 (m, 3H) , 7.3 - 7.5 (m, 2H) , 7.70 (s, IH) , 7.92 (d, IH, J=9) . M.S. : m/e 265 (M+, 100) .
EXAMPLE 30 6-Amino-4-(p-butoxyanilino) uinoline hydrochloride The title compound was prepared from the corresponding 6-nitro compound by catalytic reduction of the nitro group followed by treatment with HCl in ether. The 6-nitro-4-(p- butoxyanilino)quinoline compound was prepared in an analogous fashion to Example 9 with the modification that 4- nitroaniline was used as the starting material instead of 6- aminoindazole and p-butoxyaniline was used in the displacement of the 4-chloro substituent instead of m- anisidine.
JH NMR: £ 0.96 (t, 3H, J=6) , 1.44 (m, 2H) , 1.72 (m, 2H) , 4.02 (t, 2H, J=6), 6.52 (d, IH, J=7) , 7.08 (d, 2H, J=8) , 7.32 (d, 2H, J=8), 7.50 (d, IH, J=9) , 7.72 (s, IH) , 7.88 (d, IH, J=8) , 8.22 (br Ξ, IH) .
M.S. : m/e 307 (M+, 100) .
EXAMPLE 31 6-Amino-4- (3 , 4-difluoroanilino) -2-phenylquinoline hydrochloride
The title compound was prepared by a procedure similar to that described in Example 12.
JH NMR: £ 6.98 (s, IH) , 7.4 - 7.8 (m, 8H) , 7.90 (d, 2H, J=7), 8.20 (d, IH, J=9) .
M.S. : m/e 347 (M+, 100) . Analysis: Calc'd for C21H15N3F2«2HC1: C, 60.01; H, 4.08; N, 10.00%. Found: C, 60.07; H, 4.21; N, 9.79%.
EXAMPLE 32 4- (p-Cyclohexylmetho yanilino) -2-phenyl-6- ureidoquinoline hydrochloride
This compound was prepared from the corresponding 6- amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline with trichloroacetyl isocyante in THF followed by cleavage of the trichloroacetyl group with methanol/sulfuric acid. The hydrochloride salt was formed by treatment with HCl in ether.
XH NMR: £ 1.0 - 1.3 (m, 5H) , 1.6 - 1.9 (m, 6H) , 3.80 (d, IH, J=5) , 6.28 (br s, 2H) , 6.74 (s, IH) , 7.06 (d, 2H, J=8) , 7.38 (d, 2H, J=8) , 7.6 (m, 3H) , 7.78 (m, 2H) , 7.96 (d, IH, J=9) , 8.10 (d, IH, J=9) , 8.58 (s, IH) , 9.32 (s, IH) . M.S. : m/e 466 (M+, 30) .
High Resolution Mass Spectrum: Calc'd for C29H30N4O2: 466.2369. Found: 466.2396.
EXAMPLE 33 6-Acetamido-4-(p-cyclohexylmethoxyanilino) -2- phenylquinoline hydrochloride
This compound was prepared from the corresponding 6- amino-4-(p-cyclohexylmethoxyanilino)-2-phenylquinoline with acetic anhydride, DMAP, and triethylamine in methylene chloride, followed by treament with HCl to form the hydrochloric salt.
XH NMR: £ 1.0 - 1.3 (m, 5H) , 1.6 - 1.9 (m, 6H) , 2.18 (s, 3H) , 3.82 (d, 2H, J=6) , 6.80 (s, IH) , 7.08 (d, 2H, J=9) , 7.42 (d, 2H, J=9), 7.6 (m, 3H) , 7.83 (d, 2H, J=7) , 7.96 (d, IH, J=9), 8.26 (d, IH, J=9) , 8.95 (s, IH) . M.S.: m/e 465 (M+, 100).
High Resolution Mass Spectrum: Calc'd for C30H31N3O2: 465.2416. Found: 465.2434. EXAMPLE 34 N4-[4-(Cyclohexylmethyloxy)phenylI-2-methylquinolin-4,8- diamine Hydrochloride Hemihvdrate
A. N-[4-(Cyclohexylmethyloxy)phenyll-2-methyl-8- nitroquinolin-4-amine Hydrochloride Hydrate
A solution of 1.0 g (4.5 mmol) of 4-chloro-2-methyl-8- nitroquinoline, 1.0 g (4.9 mmol) of 4-(cyclohexylmethyloxy)- aniline and 30 mL of ethanol was heated under reflux for five hours. After cooling to room temperature, the reaction solution was evaporated to a residue which was slurried in in diethyl ether and filtered to furnish 2.0 g (99%) of N- [4-(cyclohexylmethyloxy)phenyl]-2-methyl-8-nitroquinolin-4- amine hydrochloride hydrate: m.p. 211-214°C (uncorr.).
Anal. Calcd for C23H25N303, HCl, H20 (445.94): C, 61.94; H, 6.33; N, 9.43. Found: C, 62.24; H, 6.13; N, 9.14.
B. N4-[4-(Cyclohexylmethyloxy)phenyll-2-methyl- quinolin-4,8-diamine Hydrochloride Hemihvdrate
Palladium-on-carbon (180 mg of 5% material) was added to a solution of 100 L of ethanol and 1.8 g (4.0 mmol) of the nitroquinoline described immediately above. The mixture was then shaken in a Parr apparatus under three atmospheres of hydrogen for an hour. The mixture was filtered, and the filtrate was evaporated under reduced pressure to give 1.0 g (61%) of N4-[4-(cyclohexylmethyloxy)phenyl]-2-methyl- quinolin-4,8-diamine hydrochloride hemihydrate: m.p. 274-277°C. A small portion was recrystallized from acetic acid for analysis; m.p. 280-284°C.
Anal. Calcd for C23H27N30, HCl, 0.5 H20 (406.945): C, 67.88; H, 7.18; N, 10.33. Found: C, 67.91; H, 6.89; N, 10.21.
EXAMPLE 35 4 - ( 4 - Butv lpheny l am i n o )' - 2 -m e thy l qu i n o l i n - 6 - o l Hydrobromide Hydrate
A. N- ( 4 -Butylphenyl ) -6-methoxy-2-methylquinolin-4- amine . In a 100 mL three-neck round bottom flask under a nitrogen atmosphere and with magnetic stirring, a solution of 502 mg (2 . 42 mmol) of 4-chloro-6-methoxy-2-methyl- quinoline, 450 mg (3.02 mmol) of 4-butylaniline and 25 mL of ethanol was heated under reflux for an hour. The reaction solution was evaporated under reduced pressure to furnish a residue which was then chromatographed on silica gel (eluant 9:1 chloroform-methanol) to give 511 mg of the desired product. The sample was recrystallized from ethanol-water to give 320 mg (41%) of pure N-(4-butylphenyl)-6-methoxy-2- methylquinolin-4-amine: m.p. 200-201°C.
Anal. Calcd for C2IH24N20 (320.422): C, 78.82; H, 7.56; N, 8.75. Found: C, 78.49; H, 7.45; N, 8.71.
B. 4-(4-Butylphenylamino) -2-methylquinolin-6-ol Hydrobromide Hydrate
Under a nitrogen atmosphere and with magnetic stirring, a solution of 17.5 mL of 48% hydrobromic acid and 142 mg (0.442 mmol) of N-(4-butylphenyl)-6-methoxy-2-methyl- quinolin-4 -amine was heated under reflux overnight. The reaction mi_ ure was allowed to cool to room temperature whereupon a precipitate formed. The mixture was filtered and washed with ethyl acetate to afford 92 mg of solid material. This was recrystallized from 2-propanol to give
55 mg (31%) of 4-(4-butylphenylamino)-2-methylquinolin-6-ol hydrobromide hydrate: m.p. 264-265°C.
Anal. Calcd for C20H22N20, HBr, H20 (405.324) : C, 59.27; H, 6.22; Br, 19.71; N, 6.91. Found: C, 59.52; H, 6.31; Br, 19.32; N, 6.84.
EXAMPLE 36 4- (4-Chlorophenylamino -2-methylquinolin-6-ol Hydrobromide Hydrate
A. N- (4-Chlorophenyl) -6-methoxy-2-methylquinolin-4- amine hydrochloride
In a manner similar to that described in Example 35, Part A, 4-chloro-6-methoxy-2-methylquinoline and 4-chloro- • aniline -were " transformed into N-(4-chlorophenyl)-6-. methoxy-2-methylquinolin-4-amine hydrochloride: m.p. 305- 307°C.
Anal. Calcd for C17H15C1N20, HCl (335.225): C, 60.90; H, 4.81; N, 8.36. Found: C, 60.92; H, 4.78; N, 8.33. B. 4-f 4-Chlorophenylamino) -2-methylquinolin-6-ol Hydrobromide Hydrate
In a manner similar to that described in Example 35, Part B, N-(4-chlorophenyl) -6-methoxy-2-methylquinolin-4- amine hydrochloride was transformed into the title compound: m.p. 308-310°C.
Anal. Calcd for Cι6H13ClN20, HBr, H20 (383.665): C, 50.09; H, 4.20; N, 7.30. Found: C, 49.68; H, 4.09; N, 7.17. EXAMPLE 37
4-(4-Chlorophenylamino) -2 -pheny l uinol in-6-ol Hydrobromide Dihydrate
A. N- (4-chlorophenyl) -6-methoxy-2-phenylquinolin-4- amine Hydrochloride Hydrate In a manner similar to that described in Example 35, part A, 4-chloro-6-methoxy-2-phenylquinoline and 4- chloroaniline were transformed into 1.2 g (80%) of the title compound: m.p. > 250°C.
Anal. Calcd for C22H ClN20, HCl, H20 (415.306) : C, 63.62; H, 4.85; N, 6.75. Found: C, 63.68; H, 4.86; N, 6.77.
B. 4- (4-Chlorophenylamino) -2-phenylquinolin-6-ol Hydrobromide Dihydrate
In a manner similar to that described in Example 35, Part B, N-(4-chlorophenyl) -6-methoxy-2-phenylquinolin-4- a ine hydrochloride hydrate was transformed into the title compound: m.p. 180-185°C (decomp.).
Anal. Calcd for C21HI5C1N20, HBr, 2H20 (463.747):
C,54.39; H, 4.35; N, 6.04. Found: C, 54.14; H, 3.82; N, 5.91.
EXAMPLE 38 2-Methyl-4-octylaminoquinolin-6-ol Hydrobromide He ihydrate
In a 100 mL three-neck round bottom flask under a nitrogen atmosphere and with magnetic stirring, a solution of 1.0 g (4.8 mmol) of 4-chloro-6-methoxy-2-methylquinoline and 10 L of n-octylamine was heated under reflux for three hours. Upon cooling to room temperature, the reaction mixture formed a glassy solid which was filtered. This was triturated under isopropyl ether filtered and washed with additional ether. The solid was stirred with a mixture of water and ethyl acetate; insolubles were filtered and discarded; the ethyl acetate layer eventually furnished 500 mg of 6-methoxy-2-methyl-N-octylquinolin-4-amine hydrochloride: m.p. 178-179°C. Without further purification, a solution of 350 mg (1.04 mmol) of this material and 42 mL of 48% hydrobromic acid was heated reflux for 18 hours. Upon cooling, the reaction solution gave a precipitate which was filtered. The filtrate was evaporated to furnish a solid residue. The combined solids were recrystallized from hot water to give 45 mg (12%) of 2- methyl-4-octylaminoquinolin-6-ol hydrobromide hemihydrate: m.p. 176-178°C.
Anal. Calcd for CI8H26N20, HBr, 0.5 H20 (376.328): C, 57.44; H, 7.50; N, 7.45. Found: C, 57.23; H, 7.40; N, 7.23. EXAMPLE 39
4-[4-(Cyclohexylmethyloxy)phenylamino]-2-methyl- quinolin-6-ol Hydrochloride Hydrate
A. 4-Chloro-2-methylquinolin-6-ol
Under a nitrogen atmosphere in a 500 single-neck round bottom flask equipped with a condenser and a magnetic stirrer, a solution of 2.00 g (9.62 mmol) of 4-chloro-6- methoxy-2-methylquinoline and 150 mL of 48% hydrobromic acid was heated under reflux for 90 minutes. Upon cooling to room temperature, the reaction solution was evaporated under reduced pressure to afford a solid residue. The residue was slurried in chloroform filtered and washed with chloroform. The solid was next slurried in a mixture, of saturated aqueous sodium carbonate and ethyl acetate for 15 minutes, filtered and washed successively with saturated aqueous sodium carbonate, water and ethyl acetate. After air drying there was obtained 741 mg (40%) of 4-chloro-2-methyl- quinolin-6-ol: m.p. 233°C. Anal. Calcd for CjoHgClNO (193.627): C, 62.03; H, 4.16; N, 7.24. Found: C, 62.02; H, 4.07; N, 7.20.
B. 4-[4-(Cyclohexylmethyloxy)phenylamino1-2-methyl- quinolin-6-ol Hydrochloride Hydrate Under a nitrogen atmosphere in a 100 mL three-neck round bottom flask equipped with a magnetic stirrer and condenser, a solution of 580 mg (3.0 mmol) of 4-chloro-2- methylquinolin-6-ol, 707 mg (3.45 mmol) of 4-(cyclohexyl¬ methyloxy)aniline and 35 mL of ethanol was heated under reflux for three hours. Upon cooling to room temperature a precipitate formed. This was filtered, washed with ethanol, and allowed to dry. There was obtained 1.0 g of a solid that was recrystallized from n-butanol to furnish 811 mg (65%) of the title compound as yellow crystals: m.p. 318-322°C (uncorr.).
Anal. Calcd for C23H26N202, HCl, H20 (416.935): C, 66.25; H, 7.01; N, 6.72. Found: C, 66.18; H, 6.74; N, 6.75.
EXAMPLE 40 4- ( 3-Methoxyphenylamino) -2-methylquinolin-6-ol Hydrochloride
In a manner similar to that described in Example 39, Part B, 4-chloro-2-methylquinolin-6-ol and m-anisidine were converted into the title compound: m.p. 309-311°C.
Anal. Calcd for CI7HI6N202, HCl (316.779) : C, 64.45; H, 5.41; N, 8.85. Found: C, 64.15; H, 5.54; N, 8.70.
EXAMPLE 41 4-Hexylamino-2-methylquinolin-6-ol Hydrochloride Hemihemihydrate
In a manner similar to that described in Example 39, Part B, 4-chloro-2-methylquinolin-6-ol and hexylamine were transformed into the title compound: m.p. 234-236°C.
Anal. Calcd for C16H22N20, HCl, 0.25 H20 (299.321) : C, ' 64.20; H/ 7.91, N, 9.26. Found: C, 64.40; H, 7.94; N,- 9.40. EXAMPLE 42
4-Dodecylamino-2-_nethylquinolin-6-ol Hydrochloride
Hydrate
In a manner similar to that described in Example 39, Part B, 4-chloro-2-methylquinolin-6-ol and dodecylamine were transformed into the title compound: m.p. 198-203°C.
Anal. Calcd for C^H^O, HCl, H20 (396.989): C, 66.56; H, 9.39; N, 7.06. Found: C, 66.05; H, 9.41; N, 6.98.
EXAMPLE 43 4-Dodecylamino-2-methylquinolin-6-ol Methanesulfonate A stirred mixture of 1.2 g (3.0 mmol) of the hydrochloride salt described in Example 42, ethyl acetate and water was adjusted to pH 8 by the addition of aqueous 4 N sodium hydroxide. The organic phase was evaporated under reduced pressure to afford 1.0 g (2.9 mmol) of the free base as a yellow solid. This was treated with an equivalent of methanesulfonic acid. The resulting solid was triturated with isopropyl ether and then recrystallized from acetonitrile to furnish 600 mg of the title product as golden needles: m.p. 123-125°C.
Anal. Calcd for C^H^O, CH3S03H (438.62): C, 62.98; H, 8.73; N, 6.38. Found: C, 63.05; H, 8.73; N, 6.46..
EXAMPLE 44 4-Decylamino-2-methylquinolin-6-ol Methanesulfonate In the manner similar to those described in Example 39, Part B, and Example 43, 4-chloro-2-methylquinolin-6-ol and decylamine (neat at 130°C) were transformed into the title compound: m.p. 100-102°C.
Anal. Calcd for C20H30N2O, CH3S03H (410.57): C, 61.43; H, 8.34; N, 6.82. Found: C, 61.36; H, 8.39; N, 6.73.
EXAMPLE 45 4-Tetradecyl-2-methylquinolin-6-ol Hydrochloride Hydrate
A solution of 150 mg (0.78 mmol) of 4-chloro-2-methyl- quinolin-6-ol, 174 mg (0.81 mmol) of n-tetradecylamine, and
5 mL of n-butanol was heated under reflux for 24 hours.
Excess butanol was removed by codistillation with cyclohexane. The residue was chromatographed on 30 g of silica gel (eluent 1:9 methanol-dichloromethane) to furnish crude product. This was taken up in methanol, and the solution was treated with dry hydrogen chloride gas. The solution was evaporated under reduced pressure to give the title compound as crystalline material: m.p. 180-183°C.
Anal. Calcd for C24H38N20, HCl, H20 (425.04): C, 67.82; H, 9.72; N, 6.59. Found: C, 67.73; H, 9.35; N, 6.64.
EXAMPLE 46 4-f (3-Methoxyphenyl) amino]quinolin-6-ol Mixed Hydrobromide and Hydrochloride Salts
A. 4-Chloroquinolin-6-ol Hydrobromide
In a flame dried three-neck 50 mL round bottom flask equipped with a rubber septum and a mechanical stirrer, and under a nitrogen atmosphere at room temperature, 4.0 mL of 1.0 M boron tribromide in dichloromethane (Aldrich Chemical Co.) was added portionwise through gas tight syringe to a solution of 727 mg (3.75 mmol) of 4-chloro-8-methoxy- quinoline and 5.0 mL of dichloromethane. A thick solid formed immediately and after 0.5 hour of stirring another 4.0 mL portion of boron tribromide solution was added and stirring was continued overnight. The reaction mixture was treated dropwise with methanol. The solution was evaporated under reduced pressure, and the residue titurated with dichloromethane and filtered to afford 844 mg (86%) of the title compound: m.p. 243-244°C.
Anal. Calcd for C9H6C1N0, HBr (260.51): C, 41.49; H, 2.71; N, 5.38. Found: C, 41.46; H, 2.63; N, 5.27.
B. 4~r (3-Methoxyphenyl)amino] uinolin-6-ol Mixed Hydrobromide and Hydrochloride Salts
A solution of 245 mg (0.94 mmol) of 4-chloroquinolin-6- ol hydrobromide, 0.3 mL (2.72 mmol) of m-anisidine and 30 L of ethanol was heated under reflux for an hour. The reaction solution was evaporated under reduced pressure to afford a solid residue which was then slurried first in diethyl ether and then in acetone. The solid was recrystallized from hot acetone to give 200 mg (65%) of the title product: m.p. 241-243°C.
Anal. Calcd for C16H14N202, 0.6 HBr, 0.4 HCl (329.42): C, 58.33; H, 4.59; Br, 14.55; Cl, 4.30; N, 8.51. Found: C, 57.68; H, 4.52; Br, 14.17; Cl, 4.37;. N, 8.30.
EXAMPLE 47 4-[ (4-Cyclohexylmethyloxy)phenylamino1quinolin-6-ol Mixed Hydrobromide and Hydrochloride Salts
In a manner similar to that described in Example 46, Part B, 4-chloroquinolin-6-ol hydrobromide and 4-(cyclo¬ hexylmethyloxy)aniline were transformed into 267 mg (67%) of the title compound: m.p. 235-238°C.
Anal. Calcd for C22H24N202, 0.9 HBr, 0.1 HCl (424.90): C, 62.18; H, 5.93; N, 6.59. Found: C, 62.23; H, 6.32; N, 6.56.
EXAMPLE 48 4-fCyclohexylamino)quinolin-6-ol Hydrobromide Hydrate 4-(Cyclohexylamino)quinolin-6-ol Hydrobromide Hydrate. A solution of 245 mg (0.94 mmol) of 4-chloroquinolin-6-ol hydrobromide and 1.0 mL of cyclohexylamine was heated under reflux overnight. Excess volatile components of the reaction mixture were evaporated under reduced pressure. The residue was slurried with isopropyl ether and then filtered. The solids were recrystallized from hot acetic acid to afford 129 mg (40%) of the title compound: m.p. 280-285°C (dec).
Anal. Calcd for Cι5H18N202, HBr, H20 (341.24): C, 52.79; H, 6.20; N, 7.68. Found: C, 52.85; H, 6.33; N, 8.12.
EXAMPLE 49 4-(Dodecylamino)quinolin-6-ol Methanesulfonate A. 4-Chloroquinolin-6-ol
A solution of 4.99 g (18.1 mmol) of 4-chloro-6- methoxyquinoline and 50 mL of 48% hydrobromic acid is heated under reflux for seven hours. Upon cooling to room temperature, the reaction solution afforded a dark solid that was then slurried in water. The aqueous mixture was adjusted to pH 10 by the addition of 4 N sodium hydroxide. The resulting solid was filtered, washed with water and air- dried to give 1.83 g (56%) of 4-chloroquinolin-6-ol: m.p. 223°C.
B. 4-(Dodecylamino)quinolin-6-ol Methanesulfonate A mixture of 800 mg (4.4 mmol) of 4-chloroquinolin-6-ol and 4.12 g (22.2 mmol) of dodecylamine was heated at 130°C for nine hours. Upon cooling to room temperature the dark reaction mixture was slurried with isopropyl ether and then filtered. The solids were boiled with water, filtered, and then air dried to give 441 mg (30%) of the waxy free base. A solution of the free base, 92 μL of methanesulfonic acid, and methanol afforded 550 mg (29%) of the title compound as crystals: m.p. 148-149°C.
Anal. Calcd for C21H32N20, CH3S03H (424.59): C, 62.23; H, 8.48; N, 6.59. Found: C, 62.23; H, 8.55; N, 6.63.
EXAMPLE 50 4-(Decylamino)quinolin-6-ol Hydrochloride In a manner similar to that described in Example 49, Part B, 4-chloroquinolin-6-ol and decylamine were transformed into the title compound as the hydrochloride salt: m.p. 197-199°C.
Anal. Calcd for C19H28N20, HCl, (336.89): C, 67.74; H, 8.67; N, 8.31. Found: C, 67.93; H, 8.92; N, 8.16.
EXAMPLE 51 4- (4-Butylphenylamino) -2-methylquinolin-7-ol Hydrobromide Hemihvdrate
A. N-(4-Butylphenyl)-7-methoxy-2-methylquinolin-4- a ine Hydrochloride
In a manner similar to that described in Expample 35, Part A, 4-chloro-7-methoxy-2-methylquinoline and 4- butylaniline were transformed into the title compound: m.p. 245-246°C.
Anal. Calcd for C2ιH24N20, HCl (356.883): C, 70.67; H, 7.06; N, 7.85. Found: C, 70.51; H, 6.93; N, 7.81. B. 4- f 4 -Butylphenylamino ) -2 -methylquinolin-7-ol Hydrobromide Hemihvdrate
In a manner similar to that described in Example 35, Par B, N- (4-butylphenyl) -7-methoxy-2-methylquinolin-4-amine Hydrochloride was transformed into the title compound: m.p . 328-330°C.
Anal. Calcd for C20H22N2O , HBr, 0. 5 H20 (396.316) :
C, 60.92 ; H, 6. 10 ; N, 7. 07. Found: C, 60. 92 ; H, 5. 63 ; N, 7.04. EXAMPLE 52
4 - T 4- Cyclohexylmethyloxy) henylamino ] -2 -methyl- quinolin-7-ol Mixed Hydrobromide and Hydrochloride Salts
A. 4-Chloro-2-methylquinolin-7-ol Hydrobromide
In a manner similar to that described in Example 46, Part A, 4-chloro-7-methoxy-2-methylquinoline was tranformed into the title product: m.p. > 300°C.
Anal. Calcd for C10H8C1NO, HBr (274.54): C, 43.75; H, 3.30; N, 5.10. Found: C, 44.15; H, 3.21; N, 4.98.
B. 4-Chloro-2-methylquinolin-7-ol A mixture of 2.33 g (8.49 mmol) of the hydrobromide salt described above, ethyl acetate and aqueous saturated sodium carbonate was stirred for an hour. The organic phase was then washed with aqueous saturated NaCl, dried over anhydrous magnesium sulfate, filtered, and evaporated to furnish 1.6 g (100%) of 4-chloro-2-methylquinolin-7-ol.
C. 4-T4- (Cyclohexylmethyloxy) henylamino] -2- methylquinolin-7-ol Mixed Hydrobromide and Hydrochloride Salts
In a manner similar to that described in Example 46, Part B, 4-chloro-2-methylquinolin-7-ol hydrobromide and 4- (cyclohexylmethyloxy)aniline were tranformed into the title compound: m.p. 330-333°C.
Anal. Calcd for C^H^N^, 0.5 HBr, 0.5 HCl (421.14): C, 65.59; H, 6.46; N, 6.65. Found: C, 65.51; H, 6.26; N, 6.55. EXAMPLE 53 4-(Dodecylamino)-2-methylquinolin-7-ol Methanesulfonate In a manner similar to that described in Example 49, Part B, 4-chloro-2-methylquinolin-7-ol and dodecylamine were transformed into the title compound: m.p. 186-187°C.
Anal. Calcd for
Figure imgf000045_0001
CH3S03H (438.62): C, 62.98; H, 8.73; N, 6.38. Found: C, 62.90; H, 8.55; N, 6.34.
EXAMPLE 54 4-(Decylamino)-2-methylquinolin-7-ol Methanesulfonate In a manner similar to that described in Example 49, Part B, 4-chloro-2-methylquinolin-7-ol and decylamine were transformed into the title compound: m.p. 188-189°C.
Anal. Calcd for C20H30N2O, CH3S03H (410.57): C, 61.43; H, 8.34; N, 6.82. Found: C, 61.53; H, 8.51; N, 6.75. EXAMPLE 55
4-(4-Butylphenylamino)quinolin-8-ol Hydrochloride
Hydrate
A. N- (4-Butylphenyl) -8-methoχyquinolin-4-amine Hydrochloride Hydrate In a manner similar to that described in Example 35, Part A, 4-chloro-8-methoxyquinoline and 4-butylaniline were tranformed into the title compound: m.p. 132-134°C.
Anal. Calcd for C20H22N2O, HCl, H20 (360.87): C, 66.56; H, 6.98; N, 7.76. Found: C, 66.16; H, 6.85; N, 7.82. B. 4-(4-Butylphenylamino)quinolin-8-ol Hydrochloride Hydrate
In a flame dried single-neck round bottom flask equipped with a Dean-Stark trap and a condenser, a solution of 1.0 g ( 2.9 mmol) of N-(4-butylphenyl)-8-methoxy- quinolin-4-amine hydrochloride and 20 L of toluene was treated with 1.9 g (14.5 mmol) of anhydrous aluminum chloride. This was heated under reflux for five hours, and then allowed to cool to room temperature. The reaction solution was treated dropwise with water until a sticky solid formed. Work-up of the mixture eventually afforded 709 mg of crude product. This was recrystallized from water-formic acid to furnish 340 mg (34%) of the title compound: m.p. 269 °C.
Anal. Calcd for C19H20N2O, HCl, H20 (346.847) : C, 65. 79 ; H, 6. 68 ; N, 8. 07. Found: C, 65.34 ; H, 6.29 ; N, 7.84. EXAMPLE 56
4- [4- (Cyclohexylmethyloxy) phenylamino ] quinolin-8-ol Hydrochloride Hydrate
A. 4-Chloroquinolin-8-ol Hydrobromide
In a manner similar to that described in Example 46, Part A, 4-chloro-8-methoxyquinoline was tranformed into the title product: m.p. 232-233°C.
B. 4-Chloro-quinolin-8-ol
A solution of 1.3 g of the hydrobromide salt and 50 mL of water was adjusted to pH 9 by the addition of 4 N sodium hydroxide. The resulting precipitate was filtered, washed with water, and air-dried to give 790 mg (52%) of the title compound: m.p. 143-145°C.
C. 4-[4-(cyclohexylmethyloxy)phenylamino]quinolin-8- ol Hydrochloride Hydrate In a manner similar to that described in Example 46,
Part B, 4-chloro-quinolin-8-ol hydrobromide and 4-
(cyclohexylmethyloxy)aniline were tranformed into and the title product: m.p. 286-288°C (from methanol-acetonitrile) .
Anal. Calcd for C22H24N2/ HCl, H20 (402.89): C, 65.58; H, 6.75; N, 6.95. Found: C, 65.82; H, 6.19; N, 6.90.
EXAMPLE 57 4-(Dodecylamino)quinolin-8-ol Hydrochloride In a manner similar to that described in Example 49, Part B, 4-chloroquinolin-8-ol and n-dodecylamine were transformed into the title compound: m.p. 189-190°C; m/e 328 (molecular ion) ; NMR spectum consistent with assigned structure. EXAMPLE 58 4-[4-(Cyclohexylmethyloxy)phenylamino.quinolin-6,8-diol Hydrochloride
A. 6,8-Dimethoχyquinolin-4-ol In a three neck round-bottom flask equipped with a reflux condenser and a mechanical stirrer, a solution of 10.0 g (69.3 mmol) of 2,2-dimethyl-l,3-dioxan-4,6-dione (Meldrum's acid) and 46 mL (277 mmol) of triethyl orthoformate was treated with 11.1 g (72.7 mmol) of 2,4- dimethoxyaniline. The mixture was heated at 85°C for two hours. Upon cooling to room temperature, the reaction mixture was diluted with isopropyl ether and filtered to furnish 18.7 g of 5-[ (2,4-dimethoxyphenyl)aminomethylene]- 2,2-dimethyl-l,3-dioxan-4,6-dione as a bright orange solid. This solid was then added portionwise to 80 L of a boiling solution of biphenyl and diphenyl ether/biphenyl, (Dowtherm, trademark) . After the final addition heating was continued for just 5 minutes. After cooling to room temperature, the reaction mixture was stored in the refrigerator overnight, and then stirred with isopropyl ether for an hour. The solids were filtered and washed with isopropyl ether to afford 11.8 g (83%) of 6,8-dimethoxyquinolin-4-ol: m.p. 221-224°C.
B. 4-Chloro-6.8-dimethoxyquinoline A solution of 6.5 g (31.6 mmol) of 6,8-dimethoxy- quinolin-4-ol, 29 mL (316 mmol) of phosphorous oxychloride and 2.6 mL of N,N-dimethylformamide was stirred at room temperature for seven hours. The reaction solution was poured into a stirred mixture of ice and water. The aqueous mixture was washed three times with 300 mL portions of ethyl acetate, and then adjusted to pH 6 by the addition of solid sodium carbonate. 4-Chloro-6,8-dimethoxyquinoline was thus obtained as a colorless solid: yield 5.73 g (81%) . The product was recrystallized from hot water for analysis: m.p. 115-116°C.
Anal. Calcd for CnH10ClNO2 (223.66): C, 59.07; H, 4.50; N, 6.26. Found: C, 58.98; H, 4.24; N, 6.18. C. 4-Chloroquinolin-6 , 8-diol Hemihvdrate
In a manner similar to that described in Example 46, Part A, 4-chloro-6,8-dimethoxyquinoline was tranformed into 4-chloroquinolin-6,8-diol hemihydrate: m.p. 209-211°C. Anal. Calcd for C9H6C1N02, 0.5 H20 (204.61): C, 52.83;
H, 3.44; N, 6.84. Found: C, 52.95; H, 2.90; N, 6.81.
D. 4- [4- (Cyclohexylmethyloxy) phenylamino] - quinolin-6,8-diol Hydrochloride
In a manner similar to that described in Example 39, Part B, 4-chloroquinolin-6,8-diol hemihydrate and 4- (cyclohexylmethyloxy) aniline were tranformed into the title compound: m.p. 294°C (dec).
Anal. Calcd for C22H24N203, HCl (400.89): C, 65.91; H, 6.25; N, 6.98. Found: C, 65.63; H, 6.02; N, 7.05. EXAMPLE 59
4- [4- (Cyclohexylmethyloxy) phenylamino ]quinol in- 6- methanol Methanesulfonate
A. Ethyl 4-Hvdroχyquinoline-6-carboxylate
In a manner similar to that described in Example 58, Part A. , 10 g (69 mmol) of 2,2-dimethyl-l,3-dioxan-4,6-dione and 11.4 g (69 mmol) of ethyl 4-aminobenzoate were tranformed into the title product: yield 10.86 g (72%); m.p. 233-234°C.
Anal. Calcd for CI2HnN03 (217.22): C, 66.35; H, 5.10; N, 6.45. Found: C, 66.04; H, 4.92; N, 6.39.
B. Ethyl 4-Chloroquinoline-6-carboxylate
In a manner similar to that described in Example 58, Part B., 7.34 g (33.7 mmol) of ethyl 4-hydroxyquinolin-6- carboxylate was transformed into the title compound: yield 4.9 g (62%); m.p. 84-85°C.
Anal. Calcd for CI2H10ClNO2 (235.66): C, 61.16; H, 4.27; N, 5.94. Found: C, 61.35; H, 4.28; N, 5.82.
C. Ethyl 4-T4-(cyclohexylmethyloxy)phenylamino]- quinolin-6-carboxylate Hydrochloride In a manner similar to that described in Example 39, Part B., 2.0 g (8.48 mmol) of ethyl 4-chloroquinolin-6- carboxylate and 1.74 g (8.48 mmol) of 4-(cyclohexyl- methyloxy)aniline were transformed into the title compound: yield 3.41 g (92%); m.p. 251-253°C.
Anal. Calcd for C25H28N203, HCl (440.96): C, 68.09; H, 6.62; N, 6.35. Found: C, 68.00; H, 6.40; N, 6.07. D. 4-[4-(Cyclohexylmethyloxy)phenylamino]quinolin-6- methanol Methanesulfonate
A suspension of 519 mg (1.18 mmol) of the compound described in Part C, above, in water was adjusted to pH 12 by the addition 4 N sodium hydroxide, and stirred for 30 minutes. The aqueous mixture was then extracted three times with 250 mL portions of dichloromethane. The combined extracts were washed with saturated aqueous sodium chloride, and dried over anhydrous sodium sulfate. The organic phase was filtered and evaporated under reduced pressure. The residue was dried in a vacuum oven for 72 hours, and then slurried with magnetic stirring in 7 mL of dichloromethane. At room temperature, 1.5 mL of 1.0 M borane- ethylsulfide in dichloromethane (Aldrich) was added to the slurry. The reaction mixture was then heated under reflux for four hours, and then allowed to cool. Methanol was added dropwise to the reaction mixture, and stirring was continued for an hour. Volatile components were evaporated from the reaction mixture, and the residue was chromatographed on 50 g of silica gel (eluent: 5:95 methanol-dichloro- methane) to furnish crude 4-[4-(cyclohexylmethyloxy)phenyl¬ amino]quinolin-6-methanol. An additional chromatography procedure gave 40 mg of pure free base. To a methanol solution of the free base was added 10 μl> of methanesulfonic acid. Removal of the methanol led to a yellow oil which was then crystallized from 2-propanol and isopropyl ether to give the tile compound: yield 15 mg (3%) ; m.p. 158-160°C; m/e 362; NMR (deuterochloroform) showed a new peak at £ 4.69 ppm (s, 2H, CH2OH) , and no peaks indicating the presence of an ethoxy group.

Claims

CLAIMS A compound of the formula
Figure imgf000050_0001
wherein R1 is (C3-Cι8) alkyl or phenyl optionally substituted with from one to three substituents independently selected from (C -C6) alkyl, (Cj-Cg) alkoxy, halo, cyano, (C3-C8)
Figure imgf000050_0002
alkoxy wherein the cycloalkyl moiety may be substituted with from one to three (C,-C6)alkyl groups; hydroxyl, benzyloxy, carboxyl, hydroxy- (C -C^ alkyl, pyrrolidino, piperidino, morpholino and -CONHQCOOH wherein Q is (C!-C4) alkyl;
R2 is hydrogen, (Cj-C6) alkyl, (C3-C7) cycloalkyl, phenyl or phenyl-(Cj-Cg) alkyl, wherein the phenyl moieties of said phenyl and said phenyl-(Cr-C6) alkyl may be optionally substituted with from one to three substituents independently selected from (Cj-Cg) alkyl, (Cj-Cg)-alkoxy, halo, cyano and benzyloxy; each of R3 and R4 is hydrogen;
R5 is hydrogen, amino, hydroxyl, 5-pyrazolyl, guanidino, hydroxy-( -Cg) alkyl, -NHC(=NR8)R9, -NHS02Ru, -NHCOR12 or ureido; or R4 and R5, together with the carbons to which they are attached, form a group of the formula
Figure imgf000051_0001
R B
wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R4 to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R5 to the quinoline nucleus;
R6 is hydrogen, hydroxyl, amino, guanidino, -NHC(=NR8)R9, -NHCOR13, -NHS02R13 or ureido;
R7 is hydrogen, halo, hydroxyl, amino, -NHC(=NR8)R9, -NHS02R14, -NHCOR14, ureido or guanidino;
R8 and R9 are independently selected from hydrogen, phenyl and (C^Cg)alkyl;
R11, R12, R13 and R14 are independently selected from (Cj- C6) alkyl and phenyl optionally substituted with halo, (Cj- C6)alkyl or (Cj-Cg)alkoxy; except for 6-amino-4-anilino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-phenylquinoline hydrochloride, 6-amino-4-cyclohexylamino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-methylquinoline methanesulfonate, 6-amino-4-(p-toluidino)-2-methylquinoline methanesulfonate, 9-(p-anisidino)-2-methyl-lH-pyrazolo[3,4- f]quinoline hydrochloride, 9-(cyclohexylamino) -1H- pyrazolo[3 , 4-f]quinoline methanesulfonate, 9-
(cyclopentylamino)-lH-pyrazolo[3,4-f]quinoline methane- sulfonate, 4- (phenylamino) -2-phenylquinolin-6-ol hydrobromide, 4- (butylamino) -2-phenylquinolin-6-ol hydrobromide, 4-[ (3-methoxyphenyl) amino]-2-methyl- quinolin-7-ol hydrochloride, 4-[ (4-chlorophenyl)amino]-2- methylquinolin-7-ol hydrobromide, 4-(cyclohexylamino)-2- methylquinolin-6-ol hydrochloride, 4-[ (3-methoxyphenyl)- amino]quinolin-6,8-diol hydrochloride, and 4-(cyclohexyl- amino)quinolin-8-ol hydrochloride or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1, wherein R3, R6 and R7 are hydrogen and R4 and R5, together with the carbons to which they are attached, from a group of the formula
Figure imgf000052_0001
wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R4 to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R5 to the quinoline nucleus.
3. A compound according to claim 1 wherein R3, R4, R6 and R7 are hydrogen and R5 is amino, -NHS02Ru, -NHCOR12 or hydroxy.
4. A compound according to claim 1, wherein said compound is selected from the group consisting of:
9- (m-Anisidino) -7 -methyl-lH-pyrazolo[ 3, 4-f ] quinoline; 9- (p-Cyclohexylmethoxyanilino) - 7 -methyl -1H- pyrazolo [3 , 4-f ] quinoline;
9- (Cyclohexylamino) -7-methyl-lH-pyrazolo [3,4- f] quinoline hydrochloride;
9- (p-Cyclohexylmethoxyanilino) -lH-pyrazolo [3,4- f] quinoline;
6 -Amino -4- (p-cyclohexylmethoxyanilino) -2 - phenylquinolin ; 6-Amino-4- (p-chloroanilino) -2-phenylquinoline;
4- (p-Cyclohexylmethoxyanilino) -6-methylsulf onamido-2- phenylquinoline ;
4 -Decy lamino- 2 -methy lquino 1 in-6 - o 1 ; 4-Tetradecyl-2-methylquinolin-6-ol; 4- (Dodecylamino) quinolin-6-ol.
5. A pharmaceutical composition comprising an amount of a compound according to claim 1 effective in stimulating or enhancing the immune response of a vertebrate, and a pharmaceutically acceptable carrier.
6. A method of stimulating or enhancing the immune response of a vertebrate, comprising administering to said vertebrate an immune response stimulating or enhancing amount of a compound according to claim 1.
7. A radiolabelled of a compound according to claim 1.
8. A radiolabelled compound corresponding to claim 8, wherein said radiolabelled compound is a compound according to claim 1 wherein one or more of the hydrogen atoms is replaced with tritium or one or more of the carbon atoms is replaced with a carbon-14 isotope thereof.
9. A process for making a compound of the formula
Figure imgf000053_0001
wherein R1 is (C3-C18) alkyl or phenyl optionally substituted with from one to three substituents independently selected from (Cj-Cg) alkyl, (Cj-Cg) alkoxy, halo, cyano, (C3-C8) cycloalkyl-(Cj-Cg)alkoxy wherein the cycloalkyl moiety may be substituted with from one to three (C,-C6)alkyl groups; hydroxyl, benzyloxy, carboxyl, hydroxy-(Cj-Cg) alkyl, pyrrolidino, piperidino, morpholino and -CONHQCOOH wherein Q is (C,-C4) alkyl;
R2 is hydrogen, (C,-C6) alkyl, (C3-C7) cycloalkyl, phenyl or phenyl-( -Cg) alkyl, wherein the phenyl moieties of said phenyl and said phenyl-(Cj-Cg) alkyl may be optionally substituted with from one to three substituents independently selected from (Cj-Cg) alkyl, (C^Cg)-alkoxy, halo, cyano and benzyloxy; each of R3 and R4 is hydrogen;
R5 is hydrogen, amino, hydroxyl, 5-pyrazolyl, guanidino, hydroxy-(Ci-Cg) alkyl, -NHC(=NR8)R9, -NHS02Ru, -NHCOR12 or ureido; or R4 and R5, together with the carbons to which they are attached, form a group of the formula
Figure imgf000054_0001
R B
wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R4 to th quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R5 to the quinoline nucleus; R6 is hydrogen, hydroxyl, amino, guanidino, -NHC(=NR8)R9, -NHCOR13, -NHS02R13 or ureido;
R7 is hydrogen, halo, hydroxyl, amino, -NHC(=NR8)R9, -NHS02R14, -NHCOR14, ureido or guanidino;
R8 and R9 are independently selected from hydrogen, phenyl and Cι-C6)alkyl;
R11, R12, R13 and R14 are independently selected from (Cj- C6) alkyl and phenyl optionally substituted with halo, (Cj- C6)alkyl or (Cj-Cg)alkoxy; except for 6-amino-4-anilino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-phenylquinoline hydrochloride, 6-amino-4-cyclohexylamino-2-phenylquinoline hydrochloride, 6-amino-4-(m-anisidino)-2-methylquinoline
' methanesulfonate, 6-amino-4-(p-toluidino)τ2-methylquinoline- methanesulfonate, 9-(p-anisidino)-2-methyl-lH-pyrazolo[3,4- f]quinoline hydrochloride, 9-(cyclohexylamino) -1H- pyrazolo[3 , 4-f] quinoline methanesulfonate, 9-
(cyclopentylamino)-lH-pyrazolo[3,4-f]quinoline methane- sulf onate, 4- (phenylamino) -2-phenylquinolin-6-ol hydrobromide, 4- (butyla ino) -2-phenylquinolin-6-ol hydrobromide, 4-[ (3-methoxyphenyl) amino] -2-methyl- quinolin-7-ol hydrochloride, 4-[ (4-chlorophenyl)amino]-2- methylquinolin-7-ol hydrobromide, 4- (cyclohexylamino) -2- methylquinolin-6-ol hydrochloride, 4-[ (3-methoxyphenyl)- amino]quinolin-6,8-diol hydrochloride, and 4- (cyclohexyl¬ amino) quinolin-8-ol hydrochloride or a pharmaceutically acceptable salt thereof comprising reacting a compound of the formula V
Figure imgf000055_0001
wherein R2, R3, R4, R5, R6 and R7 are described as above with an amine of the formula H2NR! wherein R1 is defined as above.
10. A process according to claim 9 wherein R3, R6 and R7 are hydrogen and R4 and R5, together with the carbons to which they are attached, from a group of the formula
Figure imgf000055_0002
wherein the carbon of group A labelled with an asterisk (*) represents the point of attachment of R4 to the quinoline nucleus and the carbon of group A adjacent to it represents the point of attachment of R5 to the quinoline nucleus.
11. A process according to claim 9 wherein R3, R4, R6 and R7 are hydrogen and R5 is amino, -NHS02Rπ, -NHCOR12 or hydroxy.
12. A process according to claim 9 wherein the compound formed is:
9- (m-Anisidino) -7-methyl-lH-pyrazolo [3 , 4-f ] quinoline; 9- (p-Cyclohexylmetho yanili o ) -7 -methyl- 1H- pyrazolo [3, -f] quinoline;
9- (Cyclohexylamino) -7 -methyl- lH-pyrazolo [3,4- f] quinoline hydrochloride;
9- (p-Cyclohexylmethoxyanilino) -lH-pyrazolo [3 , 4- f] quinoline; 6-Amino-4- (p-cycloήexylmethoxyanilino) -2 - phenylquinoline ;
6-Amino-4- (p-chloroanilino) -2-phenylquinoline; 4- (p-Cyclohexylmethoxyanilino) -6-methylsulf onamido-2- phenylquinoline ; 4-Decylamino-2-methylquinolin-6-ol ;
4-Tetradecyl-2-methylquinolin-6-ol; 4- (Dodecylamino) quinolin-6-ol .
PCT/US1992/005435 1991-08-02 1992-07-01 Quinoline derivatives as immunostimulants WO1993003030A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP92916871A EP0597003A1 (en) 1991-08-02 1992-07-01 Quinoline derivatives as immunostimulants
US08/190,113 US5506235A (en) 1991-08-02 1992-07-01 Quinoline derivatives as immunostimulants
JP5503553A JPH06504294A (en) 1991-08-02 1992-07-01 Quinoline derivatives as immunostimulants
FI940469A FI940469A (en) 1991-08-02 1994-02-01 Quinoline derivatives as immunostimulants

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US74082591A 1991-08-02 1991-08-02
US740,825 1991-08-02

Publications (1)

Publication Number Publication Date
WO1993003030A1 true WO1993003030A1 (en) 1993-02-18

Family

ID=24978239

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1992/005435 WO1993003030A1 (en) 1991-08-02 1992-07-01 Quinoline derivatives as immunostimulants

Country Status (8)

Country Link
US (1) US5506235A (en)
EP (1) EP0597003A1 (en)
JP (1) JPH06504294A (en)
CA (1) CA2114727C (en)
FI (1) FI940469A (en)
IE (1) IE922485A1 (en)
PT (1) PT100751A (en)
WO (1) WO1993003030A1 (en)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009294A1 (en) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Substituted heteroaromatic compounds and their use in medicine
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
US6638945B1 (en) 1999-05-08 2003-10-28 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
US6809106B1 (en) 1999-05-08 2004-10-26 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
US6841680B2 (en) * 2000-11-06 2005-01-11 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
US7173136B2 (en) 2002-11-02 2007-02-06 Astrazeneca Ab 3-Cyano-quinoline derivatives
US7173135B2 (en) 2002-07-09 2007-02-06 Astrazeneca Ab Substituted 3-cyanoquinolines as MEK inhibitors
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
WO2007147576A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Aktiengesellschaft Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them
WO2007147578A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Aktiengesellschaft Quinoline derivatives, their preparation, their use, and medicaments comprising them
US7381824B2 (en) 2003-12-23 2008-06-03 Agouron Pharmaceuticals, Inc. Quinoline derivatives
US8987301B2 (en) 2009-11-07 2015-03-24 Merck Patent Gmbh Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
US10266536B2 (en) 2013-03-14 2019-04-23 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100489174B1 (en) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-anilinoquinazoline derivatives
US5919776A (en) * 1996-12-20 1999-07-06 Merck & Co., Inc. Substituted aminoquinolines as modulators of chemokine receptor activity
DE102004063223A1 (en) * 2004-12-22 2006-07-13 Schering Ag New quinoline derivatives are ephrin receptor kinase inhibitors useful for the treatment of e.g. blood vessels diseases, hyperproliferations, chronic or acute neurodegenerative diseases, psoriasis, eczema and scleroderma
MX2007007645A (en) * 2004-12-22 2007-08-06 Bayer Schering Pharma Ag Quinoline derivative, use and production thereof, and drug containing the same.
DE102007024470A1 (en) 2007-05-24 2008-11-27 Bayer Schering Pharma Aktiengesellschaft New sulfoximine-substituted quinoline and/or quinazoline derivatives are erythropoietin-producing hepatoma amplified sequence-receptor kinase inhibitors useful to prepare medicaments to e.g. treat endometriosis and stenosis
EP2072502A1 (en) 2007-12-20 2009-06-24 Bayer Schering Pharma Aktiengesellschaft Sulfoximide substituted chinolin and chinazolin derivatives as kinase inhibitors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB980394A (en) * 1962-09-12 1965-01-13 Allen & Hanburys Ltd Quinaldinium derivatives
FR5389M (en) * 1966-02-04 1967-09-18
FR2047882A1 (en) * 1969-06-20 1971-03-19 Roussel Uclaf Analgesic antiinflammatory 4-(2-alkoxy - phenylamino-quinolines and intermediates
US3859291A (en) * 1973-10-01 1975-01-07 Morton Norwich Products Inc 9-(p-anisidino)-7-methyl-(1h)-pyrazolo(3,4-f)quinoline
FR2321291A1 (en) * 1975-08-18 1977-03-18 Serdex NEW DERIVATIVES OF AMINO-4 QUINOLEINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS
EP0187705A2 (en) * 1985-01-08 1986-07-16 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
EP0326330A2 (en) * 1988-01-29 1989-08-02 DowElanco Quinoline, quinazoline, and cinnoline fungicides

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919238A (en) * 1973-06-06 1975-11-11 Morton Norwich Products Inc 9-(Substituted amino)imidazo(4,5-f) quinolines
US4716168A (en) * 1985-01-08 1987-12-29 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB980394A (en) * 1962-09-12 1965-01-13 Allen & Hanburys Ltd Quinaldinium derivatives
FR5389M (en) * 1966-02-04 1967-09-18
FR2047882A1 (en) * 1969-06-20 1971-03-19 Roussel Uclaf Analgesic antiinflammatory 4-(2-alkoxy - phenylamino-quinolines and intermediates
US3859291A (en) * 1973-10-01 1975-01-07 Morton Norwich Products Inc 9-(p-anisidino)-7-methyl-(1h)-pyrazolo(3,4-f)quinoline
FR2321291A1 (en) * 1975-08-18 1977-03-18 Serdex NEW DERIVATIVES OF AMINO-4 QUINOLEINE, THEIR PREPARATION AND THEIR THERAPEUTIC APPLICATIONS
EP0187705A2 (en) * 1985-01-08 1986-07-16 Norwich Eaton Pharmaceuticals, Inc. Imidazo(4,5-f)quinolines useful as immunomodulating agents
EP0326330A2 (en) * 1988-01-29 1989-08-02 DowElanco Quinoline, quinazoline, and cinnoline fungicides

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Annales Pharmaceutiques Francaises, vol. 35, nos. 7-8, 1977, (Paris, FR), A. DESVIGNES et al.: "Recherche sur les aminoquinoléines. XVIII. Activité antibactérienne et antifongique in vitro d'alkylamino-4 quinoléines à longues chaînes", pages 239-247, see complete document *
Chimie Thérapeutique, no. 2, March-April 1973, (Paris, FR), A. ALLAIS et al.: "Recherche de composés analgésiques non narcotiques. Etude de nouvelles (alcoxycarbonyl-2' phénylamino)-4 quinoléines et de molécules apparentées", pages 154-168, see page 163, no. 2456; page 158, no. 2310 *
European Journal of Medicinal Chemistry, no. 6, November-December 1976, (Paris, FR), S. RENAULT et al.: "Recherche sur les aminoquinoléines. XIV : alkylamino-4 quinoléines à longues chaînes à activité amoebicide potentielle", pages 547-554, see complete document *
European Journal of Medicinal Chemistry, no. 6, November-December 1976, (Paris, FR), S. RENAULT et al.: "Recherche sur les aminoquinoléines. XV : alkylamino-4 quinoléines et quinaldines à longues chaînes à activité amoebicide potentielle", pages 555-560, see complete document *
European Journal of Medicinal Chemistry, no. 6, November-December 1976, (Paris, FR), S. RENAULT et al.: "Recherche sur les aminoquinoléines. XVI : alkylamino-4 quinoléines et quinaldines à longues chaînes à activité amoebicide potentielle", pages 561-565, see complete document *

Cited By (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996009294A1 (en) * 1994-09-19 1996-03-28 The Wellcome Foundation Limited Substituted heteroaromatic compounds and their use in medicine
WO1998013350A1 (en) * 1996-09-25 1998-04-02 Zeneca Limited Qinoline derivatives inhibiting the effect of growth factors such as vegf
US6809097B1 (en) 1996-09-25 2004-10-26 Zeneca Limited Quinoline derivatives inhibiting the effect of growth factors such as VEGF
US6638945B1 (en) 1999-05-08 2003-10-28 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
US6809106B1 (en) 1999-05-08 2004-10-26 Astrazeneca Ab Quinoline derivatives as inhibitors of MEK enzymes
US7160889B2 (en) 2000-04-07 2007-01-09 Astrazeneca Ab Quinazoline compounds
US7067532B2 (en) 2000-11-02 2006-06-27 Astrazeneca Substituted quinolines as antitumor agents
US7504416B2 (en) 2000-11-02 2009-03-17 Astrazeneca Ab 4-substituted quinolines as antitumor agents
US7253184B2 (en) 2000-11-02 2007-08-07 Astrazeneca Ab 4-Substituted quinolines as antitumor agents
US7402583B2 (en) 2000-11-02 2008-07-22 Astrzenca Ab Substituted quinolines as antitumor agents
US6841680B2 (en) * 2000-11-06 2005-01-11 Astrazeneca Ab N-type calcium channel antagonists for the treatment of pain
US7173135B2 (en) 2002-07-09 2007-02-06 Astrazeneca Ab Substituted 3-cyanoquinolines as MEK inhibitors
US7173136B2 (en) 2002-11-02 2007-02-06 Astrazeneca Ab 3-Cyano-quinoline derivatives
US7923457B2 (en) 2003-12-23 2011-04-12 Agouron Pharmaceuticals Inc. Quinoline derivatives
US7381824B2 (en) 2003-12-23 2008-06-03 Agouron Pharmaceuticals, Inc. Quinoline derivatives
WO2007147578A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Aktiengesellschaft Quinoline derivatives, their preparation, their use, and medicaments comprising them
US7598263B2 (en) 2006-06-21 2009-10-06 Bayer Schering Pharma Ag Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them
WO2007147576A1 (en) * 2006-06-21 2007-12-27 Bayer Schering Pharma Aktiengesellschaft Cyanoquinoline derivatives, their preparation, their use, and medicaments comprising them
US8987301B2 (en) 2009-11-07 2015-03-24 Merck Patent Gmbh Heteroarylaminoquinolines as TGF-beta receptor kinase inhibitors
US10266536B2 (en) 2013-03-14 2019-04-23 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
US10717739B2 (en) 2013-03-14 2020-07-21 Convergene Llc Methods and compositions for inhibition of bromodomain-containing proteins
WO2017091661A1 (en) * 2015-11-25 2017-06-01 Strovel Jeffrey William Bicyclic bet bromodomain inhibitors and uses thereof
US10508106B2 (en) 2015-11-25 2019-12-17 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
US11028079B2 (en) 2015-11-25 2021-06-08 Convergene, Llc Small molecule BET bromodomain inhibitors and uses thereof
AU2016361441B2 (en) * 2015-11-25 2021-08-12 Convergene Llc Bicyclic BET bromodomain inhibitors and uses thereof
EP4050005A1 (en) * 2015-11-25 2022-08-31 Convergene Llc Bicyclic bet bromodomain inhibitors and uses thereof

Also Published As

Publication number Publication date
IE922485A1 (en) 1993-02-10
FI940469A0 (en) 1994-02-01
PT100751A (en) 1993-09-30
US5506235A (en) 1996-04-09
CA2114727C (en) 1996-12-10
FI940469A (en) 1994-02-01
JPH06504294A (en) 1994-05-19
CA2114727A1 (en) 1993-02-18
EP0597003A1 (en) 1994-05-18

Similar Documents

Publication Publication Date Title
WO1993003030A1 (en) Quinoline derivatives as immunostimulants
AP1164A (en) Substituted 6,6-hetero-bicyclic derivatives.
US3700673A (en) 3-4-dihydrobenzo(b) (1,7)naphthyridin-1(2h)-ones
US4698348A (en) 1H-imidazo[4,5-c]quinolines and their use as bronchodilating agents
Koga et al. Structure-activity relationships of antibacterial 6, 7-and 7, 8-disubstituted 1-alkyl-1, 4-dihydro-4-oxoquinoline-3-carboxylic acids
EP0322133B1 (en) Quinazoline derivatives
AU624118B2 (en) Antibacterial agents
KR880002232B1 (en) Preparation process for quinoline derivatives and their salts
KR100206200B1 (en) Quinoline derivatives
KR930005002B1 (en) Process for preparing pyridone carboxylic acid derivatives
CZ99693A3 (en) Amino quinolone derivatives substituted by aryl or aromatic heterocyclic groups
DK165921B (en) 1 H-IMIDAZOOE4,5 CAAQUINOLIN-5-oxy compounds
EP0235762A1 (en) 8-Position substituted quinolone-carboxylic acid derivatives and process for their preparation
JPH0232058A (en) 4-amino-3-carboxyquinolines and naphthylidenes, production thereof and use thereof as drug
Veronese et al. Tin (IV) chloride-promoted synthesis of 4-aminopyridines and 4-aminoquinolines
US3563981A (en) Alkylidene aromatic-aminomethylene-malonates and their preparation
EP0397040A2 (en) N-heteroaryl-4-quinolinamines, a process for their preparation and their use as medicaments
JPH0311067A (en) Excitatory amino acid antagonist
PT80546B (en) Process for the preparation of quinolinecarboxylic acid derivatives
US4996213A (en) Derivatives of 4-amino 3-carboxy naphthyridines and their pharmaceutical compositions
US4560692A (en) 4-Piperidino-2-phenylquinolines
Jung et al. Synthesis of 4‐hydroxyquinolin‐2 (1H)‐one analogues and 2‐substituted quinolone derivatives
NO843292L (en) PROCEDURE FOR THE PREPARATION OF NEW KINOLON DERIVATIVES
US6693114B2 (en) 4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxamides as antiviral agents
JPH0789966A (en) Pyrrolo(1,2-a)(4,1)benzoxazepine derivative

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): CA FI JP US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LU MC NL SE

WR Later publication of a revised version of an international search report
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 08190113

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 1992916871

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2114727

Country of ref document: CA

Ref document number: 940469

Country of ref document: FI

WWP Wipo information: published in national office

Ref document number: 1992916871

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1992916871

Country of ref document: EP